

Mara Dierssen

Group leader, Cellular and Systems Neurobiology


Systems Biology Program, CRG

ORCID: 0000-0003-0853-6865

Goals & Highlights

The Dierssen lab is centered on understanding cognition and behavior and their perturbation in intellectual disability. Our main question is:

What are the changes in neuronal architecture and connectivity that disrupt cortical and hippocampal function, in genetic cognitive disorders? In other words, what is the multi-scale link from molecular alterations to impaired cognition and behavior?



We are an interdisciplinary team of physicists, bioinformaticians and experimental biologists, and we focus on **data collection** (behavior, 3D imaging, genomic data) of many variables of the system (longitudinal behavioral analysis, population based analysis in neuronal networks, gene expression patterns). We take advantage of **computer modeling and bioinformatics analysis** (gene networks, neuronal network modeling, etc.) to tackling classical unresolved questions in the field, such as: (a) pathological disturbances of structural optimality in single cell and neuronal networks, (b) genomic dependence of cognitive disturbances, (c) identification of predictive non-invasive biomarkers, (d) discovery of pro-cognitive therapies.

Highlights

Dr. Dierssen has made important contributions to the understanding of Down syndrome pathology and other genetic mental illnesses. She uncovered specific neuronal network disturbances and candidate genes in intellectual disability and psychiatric disorders, and made significant contributions to disentangle their underlying mechanisms. Based on our results, we discovered the first drug treatment

that is efficacious in improving cognition in Down syndrome and Fragile X syndrome. Her work has led to 155 publications including some in high-profile journals (see publication list) such as *Lancet Neurology*, *Neuropsychopharmacology*, *The Journal of Neuroscience*, *Scientific Reports* or *eLife*, most of which I am senior author with an exponential increase in the number of citations that reached 5.098 (h index 2018: **43**). Her main discoveries include:

1. The discovery of the lack of a stable structural trace of **experience-dependent neuroplasticity** a fundamental mechanism involved in learning and memory Down syndrome brains (*Cerebral Cortex*, 2003; *Lancet Neurology*, 2010). This discovery led to new hypothesis in the field (*Nature Review Neuroscience* 2012)

2. She narrowed down the genetic dependency of Down syndrome neuronal and learning phenotypes. Specifically, we found that *in vivo* overexpression of **Dyrk1A, recapitulates Down syndrome phenotypes at different levels** (*Human Molecular Genetics* 2001, *American Journal of Human Genetics*, 2008, *Cerebral Cortex* 2012, *The Journal of Neuroscience*, 2016 Comment in: <http://neurosciencenews.com/cerebral-cortex-down-syndrome-3972/>)

3. She discovered **new candidate genes involved in mental illnesses**. Specifically we discovered the involvement of **NTRK3 gene in panic disorder** and of the **CHRNA5/A3/B4 genomic cluster in nicotine and alcohol abuse** (*Human Molecular Genetics* 2008, *Drug Alcohol Dependency*, 2012, *Acta Neuropathologica*, 2014, *Journal of Neuroscience* 2013, *Neuropsychopharmacology*, 2017)

4. She discovered the **first successful pro-cognitive treatment for Down syndrome**, which rescues cognitive phenotypes and also increases functional brain connectivity, (*Lancet Neurology*, 2017. See comment in: <http://www.sciencemediacentre.org/expert-reaction-to-downs-syndrome-and-green-tea-compound/>). We also contributed to new molecular targets for the treatment of Fragile X (*Nature Medicine*, 2013)

5. Her lab developed a **high-throughput phenotypic cluster** that has concentrated in developing new phenotyping strategies and tools. This has led to a number of very productive collaborations along the years (*Neuron*, 2013; *Elife*, 2018; *Science Report*, 2017 etc.)

Education

1985	Degree in Medicine, University of Cantabria, Santander, Spain
1986	Master Thesis in Neuropharmacology University of Cantabria
1989	PhD in Neurosciences, University of Cantabria
1990-1993	Postdoctoral at Autonomous University of Barcelona (UAB)
1991	Diploma Radioactive Autonomous University of Barcelona

Professional experience

1993 - 1997	Assistant Professor/Group leader, University of Cantabria (Spain)
1997 - 2001	Senior researcher, Institute of Oncology Research-IRO, Barcelona

1997 - 2006 Professor (Psychophysiology). Ramón Llull University, Barcelona
2002 - 2007 Junior Group leader, Centre for Genomic Regulation-CRG, Barcelona
2005 - 2015 Director of the Associated Unit for Behavioral Research (National Biotechnology Center-CSIC)
2007 - Group leader, Centre for Genomic Regulation-CRG, Barcelona, Spain
2007 - Group leader, Centre for Biomedical Research on Rare Diseases, Spain

Honors and Awards

2017 Trifermed Social Impact of Healthcare Award
2017 BigVang Medal
2016 Distinguished Alumni of the University of Cantabria
2016 Best Ideas Award for the clinical trial in Down syndrome
2014 David and Hillie Mahoney Award
2013 Ramón Trías Fargas Award
2013 & 1987 Dr. A Esteve Foundation Award
2010 Sisley-Lejeune Award
2008 Premi Nacional de Pensament i Cultura Científica
2008 Laura Iglesias award for women in science
2004 Jerome Lejeune Foundation Prize
2003 & 2008 Ramón Trias Fargas Award for Down syndrome research
2002 & 2009 Jaime Blanco Award at Down syndrome research

Selected Publications

Dr. Dierssen has a total record of 155 cited 5098 times to an **h-index of 43 (see full list at the end of the document)**

1. Disease mechanisms of intellectual disability

Ruiz-Mejias M; ...; **Dierssen M**. Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex. **The Journal of Neuroscience**. (2016) 36(13):3648-59

Pujol J, ... **Dierssen M**, de la Torre R. Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. **Cortex**. (2014) 64C:148-156. Co-corresponding

Pons-Espinal M ... **Dierssen M** Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. **Neurobiology of Disease** 60,18-31, 2013

Martinez de Lagrán M, ... **Dierssen M**. Dyrk1A Influences Neuronal Morphogenesis Through Regulation of Cytoskeletal Dynamics in Mammalian Cortical Neurons. **Cerebral Cortex**. 22(12): 2867- 77, 2012

Dierssen M, Down syndrome: the brain in trisomic mode. **Nature Review Neuroscience** 13(12): 844-58, 2012

Dierssen M, Lott I; Down syndrome: neurological complications and cognition. **The Lancet Neurology**, 9: 623-33, 2010

Dierssen M et al. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment **Cerebral Cortex** 13, 758-64, 2003

2. Disease mechanisms of psychiatric disorders

D'Amico D, .. **Dierssen M**. Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear. **Neuropsychopharmacology**. (2017) 42(2):462-472.

Espinosa-Carrasco J, ... **Dierssen M**. Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice. **Addiction Biology** (2018) Jan 10. doi: 10.1111/adb.12595. [Epub ahead of print]

Santos M, D'Amico D, Spadoni O, Amador-Arjona A, Stork O, **Dierssen M**. Hippocampal Hyperexcitability Underlies Enhanced Fear Memories in TgNTRK3, a Panic Disorder Mouse Model. **Journal of Neuroscience** 33(38): 15259-71, 2013

Molas S, Gener T, Güell J, Martín M, Ballesteros-Yáñez I, Sanchez-Vives MV, **Dierssen M**. Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice. **Acta Neuropathol Commun**. 2(1): 147, 2014

Del Pino I, ...**Dierssen M**, Canals S, Marín O, Rico B. Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. **Neuron**. 2013 79(6):1152-68.

Sahún I ... **Dierssen M**, Gruart A Dissociation between CA3-CA1 synaptic plasticity and associative learning in TgNTRK3 transgenic mice. **Journal of Neuroscience** 27, 2253-60, 2007. (Co-corresponding)

3. Translational research

De la Torre R... **Dierssen, M**. "Safety and efficacy of the combination of cognitive training and epigallocatechin-3-gallate for cognitive improvement in adults with Down syndrome: a double-blind randomised controlled trial". (2016) **The Lancet Neurology**, 15(8):801-810.

Busquets-Garcia, M. Gomis-González, T. Guegan, C. Agustín-Pavón, A. Pastor, R. de la Torre, **M. Dierssen**, R. Maldonado, A. Ozaita, Targeting the endocannabinoid system in the treatment of fragile X syndrome. **Nature Medicine** 9(5): 603-7, 2013

De la Torre R, ... **Dierssen M**. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. **Mol Nutr Food Res**. 58(2):278-88, 2014

Pujol J, ... **Dierssen M**, de la Torre R. Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. **Cortex** 64C: 148-156, 2014 (Co-corresponding)

Books and chapters (selected)

San Cristobal, B, Tastekin, I, **Dierssen M** Computational Models: how do they help to understand neurological diseases? En: Gerlai, R., Crusio, W. eds. Molecular-Genetic Techniques for Brain and Behavior Research, Elsevier. 2018

M. Dierssen and R. De la Torre Eds. Down Syndrome From Understanding the Neurobiology to Therapy, Progress in Brain Research, 197. Elsevier, 2012

Ongoing funding

Organization	Coordinator	Funding (Group/Project)	Period
EU-JPND	Dierssen	150.000€ / 1.676.474€	2018-2020
Marató TV3	Martin (UPF)	132.813€ / 398.646€	2017-2020
AGAUR	Dierssen	20.000€	2018-2019
CDTI	Dierssen	119.900€	2014-2018
Jerome Lejeune F.	Dierssen	40.000€	2016-2018
MINECO	Dierssen	387.200€	2016-2019
EU-Era NET Neuron	Ladurner (UM)	110.000€ / 1.407.868€	2014-2017
Jerome Lejeune F	Dierssen	40.000€	2013-2015
MINECO	Dierssen	338.800€ / 439.230€	2014/2016
FECYT	Dierssen	19.672€	2015/2016
AFMTéléthon	Bardoni (IPMC)	46.800€ / 164.000€	2013-2016
FRAXA Foundation	Dierssen	74.000€	2013-2015

Previous funding

2017-2020	Computational modelling of learning and memory neuronal networks. Ministerio de Economía y Competitividad (BES-2016-077416) I.P.- Mara Dierssen	88.250€
2014-2018	Elucidation of the mechanism of action of EGCG on the cognitive phenotype in Down syndrome mouse model. Ministerio de Economía y Competitividad (SVP-2013-068022) I.P.- Mara Dierssen Sotos	83.900€
2011-2013	Spanish Ministry of Health (PI11/00744). La inhibición de sobreexpresión de Dyrk1a como estrategia terapéutica para mejorar rendimiento cognitivo y prevenir el desarrollo de la Enfermedad de Alzheimer en pacientes con el Síndrome de Down. Role: CoPI	275.000€
2011-2013	Spanish Ministry of Education and Science (SAF2010-16427), Terapia "sináptica" para los trastornos cognitivos: hacia la identificación de nuevas dianas para la intervención farmacológica.	270.000€
2010-2012	Fondation Jerome Lejeune, Synaptic drugs for cognitive disorders: identifying new targets for pharmacological intervention. 30.000€	Role: PI
2009-2011	ERA-NET E-Rare (EU/FIS PS09102673) Targeting Rho-signalling, a new therapeutic avenue in fragile X syndrome (CureFXS). 167.000€	Role: PI- Coordinator
2009-2011	Marató TV3 Neregulin/ErbB4 signaling pathways and development of cortical inhibitory circuits: implications for the ethiology of schizophrenia. 348.000€	Role: Investigator
2009-2011	Reina Sofia Foundation (FP006/09) Análisis funcional de la interaccion DREAM-DYRK1A en modelos murinos de EA y síndrome de Down. 95.000€	Role: PI
2009-2011	Spanish Ministry of Health (FIS PI082038) Modelos animales para trastornos neuropsiquiaticos relacionados con la conducta compulsiva. 116.281€	Role: PI
2008-2009	Spanish Ministry of Education and Science (SAF2007-31093-E) ModF2_Aneuploidy: understanding gene dosage imbalance in human	

- health using genetics, functional genomics and systems biology.
40.000€ *Role:*
- 2007-2010 PI Spanish Ministry of Education and Science (SAF2007-60827) Papel de las isoformas del receptor de neurotrofina 3 (TrkC) en los procesos de memoria y aprendizaje relacionados con la adicción.
144.595€
- Role: PI*
- 2008-2011 Role of two isoforms of the high affinity receptor for NT-3 in learning and memory processes involved in drug abuse *Spanish Ministry of Education and Science* 119.500 €
- 2007 Pathogenesis of the similarities and differences of the cognitive patter of Williams and Down syndromes. *CIBERER, Spanish Ministry of Health* 24.000 €
- 2007-2009 Implication of Dyrk1A, a candidate gene for Down syndrome, in Alzheimer's type pathology and characterization of the neuropathological and cognitive effects of cytotoxic protofibrils from peptides derived of natural amyloid proteins in Dyrk1A mouse models. *Marató TV3 Foundation* 92.850,50 €
- 2007-2009 Molecular bases of the functional roles of TrkC receptor isoforms in hippocampal learning and memory processes *Ramón Areces Foundation* 110.000 €
- 2006-2009 Phenotypical characterization of animal models for neuropsychiatric disorders related to compulsive behavior. *PHECOMP (European Union FP6-2005-LIFESCIHEALTH-6)*. 140.010 €
- 2006–2010 Understanding gene dosage imbalance in human health using genetics, functional genomics and systems biology. *ANEUPLOIDY (European Union FP6-2005-LIFESCIHEALTH-6)* 560.237 € Coordinator: S.E. Antonarakis. PI Work package: M. Dierssen
- 2004-2007 Phenotypic characterization of mouse models of anxiety disorders: predisposition to drug abuse. *Spanish Ministry of Education and Science. (SAF2004-0280)* 92.000,00 €
- 2004-2007 Mouse models for the study of the trophic hypothesis of drug abuse. *Spanish Ministry of Science and Technology (GEN2003-20651-C06-03)* 138.000 €
- 2004-2006 Development and analysis of the efficacy of therapeutic interventions on the cognitive alteration of Down syndrome in murine models *Jerôme Lejeune Foundation* 32.000 €
- 2003-2006 Network: Mouse models of Central Nervous System disorders *Catalan Autonomous Government DURSI (CIRIT 2000XT/00083 and 2003 XT / 00093)* 32.000 €
- 2002-2005 Behavioral and pharmacological characterization of mouse models of NTRK3 overexpression *Spanish Ministry of Education and Science (SAF2001-1231)*. 82.939,67 €
- 2002-2005 Mouse models of overexpression of A3 (CHRNA3), A5 (CHRNA5) and B4 (CHRNA4) nicotinic receptor. *Marató TV3 Foundation*, 87.146,76 €
- 2002-2003 Development and analysis of the efficacy of therapeutic interventions on the cognitive alteration of Down syndrome murine models *Jerôme Lejeune Foundation* 38.000 €

- 2000-2002 Implication of Dyrk1A (Minibrain) in learning deficits associated with Down syndrome and their neuromorphological correlates: morphological and chemical characteristics of the pyramidal neuron of the cerebral cortex. *Jerôme Lejeune Foundation* 32.000 €
- 2000-2002 Validation of mouse models of MMU16 overexpression as neurodegenerative models, and gene therapy strategies. *Spanish Ministry of Health (FIS 00/0795)* 63.000 €

Co-investigator with significant contribution

As a co-investigator I have participated in the following projects with significant contribution: FP5- QLG1-CT-2002-00816. J.M.-Delabar-X. Estivill and FP6 framework, X. Estivill from the Spanish Ministry of Education and Science SAF2002-00799, Xavier Estivill, European Union (CEC -DOCE-Call Identifier QoL-2001-3-15) La Caixa Foundation and Ministry of Health of the Spanish Government

Personnel funding/short stages

- 2013-2017 PhD fellowship CONACyT to Marcos Quevedo
- 2014-2017 PhD fellowship Severo Ochoa to Mireia Ortega
- 2012-2015 PhD fellowship, AGAUR (FI 2012) to Jose Antonio Espinosa. Development of new computational methods for comparison and analysis of longitudinal data in mouse models of addiction.
- 2012 Support for Visit of Prof Jorge Busciglio Estancias de profesores e investigadores extranjeros de acreditada experiencia, en régimen de año sabático, en centros espanyoles, Ministerio de Educación (SAB2011-0107) Therapeutic potential of trombospondin 1 in Down syndrome phenotypes.
- 2012 Europe research stay to Georgios Stefos. Alexander von Humboldt Foundation, Germany. Effects of DYRK1A and RCAN1 on NGF-induced upregulation of plasminogen activation inhibitor-1 in neurons.
- 2011-2016 PhD fellowship FPI, MICINN (BES-2011-045391) to Silvina Catuara. Terapia sináptica para los trastornos cognitivos: hacia la identificación de nuevas dianas para la intervención farmacológica.
- 2010-2016 PhD fellowship la Caixa to Débora Viecili Costa Masini. Efficacy of Rho signalling molecules to treat FXS related phenotypes.
- 2010 Support for short stage of Carla Obradors AGAUR - (2009 BE2 00075)
- 2009-2013 PhD fellowship la Caixa to Davide D'Amico. Fear memories in TgNtrk3 mice, a model of panic disorder.
- 2009-2010 Support for Visit of Prof John Crabbe (OSHU). Genetic and Epigenetic factors in alcohol use disorders Agencia de gestió d'ajuts universitaris (AGAUR).
- 2008-2011 PhD fellowship to Susanna Molas Ministerio de Educación y Ciencia. CSIC (JAEPRe_07_00571). The role of NACHRs subunit in nicotine abuse and cognitive phenotypes.
- 2008 -2010 Support for the post-doctoral project of Monica Santos Fundaçao para a Ciência e a Tecnologia (SFRH/BPD/28555/2006_MJPinto). Chromatin remodelling and plasticity of the nervous system: study of the synapse structure and proteome in a mouse model of Rett syndrome.
- 2008-2009 Leonardo Da Vinci fellowship to support the master student Ornella Spadoni with the project "Understanding the impact of panic attacks on brain systems involved in the pathophysiology of panic disorder".
- 2007-2010 PhD fellowship to Carla Obradors AGAUR (2007FI 00690_Carla Obradors) Influence of the dysregulation of NTRK3 (TrkC) on the connectivity and the functionality of the cerebral cortex.

- 2007-2008 Support for short stage of Arqué Fusté, Glòria AGAUR (2007BE-100116_GArque). Cortical dysgenesis in Down syndrome.
- 2007 Support for short stage of Trutzel, Annette Caroline. Study of the amyloidogenic potential of toxic species of Tau in mouse models of Alzheimer's Disease EUROPEAN COMMISSION, (D/2006/PL-62013-2S).
- 2006-2009 IBRO International Travel Grant 2006 to Maria Martinez (IBRO_2006_Maria Martinez) to Martínez de Lagrán Cabredo, María

Previous to 2007

GRUPS CONSOLIDATS DE RECERCA

DURSI. Referencia: SGR0500008

Entidades participantes: CRG

Xavier Estivill, Cristina Fillat, Mara Dierssen Sotos, Susana de la Luna, Mariona Arbonés

Número de investigadores participantes: 5

Phenotypical characterisation of animal models for neuropsychiatric disorders related to compulsive behaviour

European Commission. PHECOMP Referencia: LSHM-CT-2007-037669

Entidades participantes: CRG

01-OCT-2006 30-SET-2009

Cuantía de la subvención: 140.010€

I.P.- Mara Dierssen Sotos

Número de investigadores participantes: 5

Understanding gene dosage imbalance in human health using genetics, functional genomics and systems biology.

European Commission. Referencia: 037627-AnEUplody

Entidades participantes: 15

01-SET-2006 30-AGO-2010

Cuantía de la subvención: 515.733€ €

Coordinator: S.E. Antonarakis. I.P. Work package Mara Dierssen Sotos

Número de investigadores participantes: 13 (del mismo centro)

Caracterización fenotípica de modelos murinos de trastornos de ansiedad: respuestas emocionales y predisposición a fenómenos de drogodependencia.

Ministerio de Ciencia y Tecnología. Referencia: SAF2004-02808

Entidades participantes: CRG

2004-2007

Cuantía de la subvención: 92.000€

I.P.- Mara Dierssen Sotos

Número de investigadores participantes: 4

Modelos Murinos para el estudio de la hipótesis trófica del abuso de sustancias: Perfiles de expresión génica

Ministerio de Ciencia y Tecnología. GEN2003-20651-C06-03

Entidades participantes: CRG

2004-2007

Cuantía de la subvención: 138.000€

I.P.- Mara Dierssen Sotos

Número de investigadores participantes: 4

Development and analysis of the efficacy of therapeutic interventions on the cognitive alteration of Down syndrome in murine models.

Fundación Jérôme Lejeune

Entidades participantes: CRG

2004-2006

Cuantía de la subvención: 32.000€

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: 6

Modelos murinos de sobreexpresión de los receptores nicotínicos A3 (*CHRNA3*), A5 (*CHRNA5*) y B4 (*CHRNA4*), contenidos en la mutación genómica DUP25, implicada en el trastorno de pánico y los trastornos fobicos

Fundació Marató TV3

Cuantía de la subvención: 87.146,76€

Entidades participantes: CRG

2002-2005

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: 4

Efectos de la sobreexpresión de genes en el Síndrome de Down y en el trastorno de ansiedad y estudio de la predisposición a la Trisomía 21 y la Mutación Genómica DUP25

Ministerio de Ciencia y Tecnología. Referencia: SAF2002-00799

Entidades participantes:

2002-2005

Cuantía de la subvención: 370.300€

I.P.- **Xavier Estivill Pallejà**

Número de investigadores participantes: ND

Understanding the chronic neurological alterations of Down Syndrome and their associated Phenotypes and development of molecular Targets for their correction European Commission. Referencia: QLRT-2001-00816

Entidades participantes:

2002-2005

Cuantía subvención: 337.500,85€

I.P.- **Xavier Estivill Pallejà**

Número de investigadores participantes: ND

1.

2. Development and análisis of the efficacy of therapeutic interventions on the cognitive alteration of Down syndrome murine models

Fundación Jérôme Lejeune. Referencia: JMLM/CD/03-123

Entidades participantes:

2002-2003

Cuantía de la subvención: 38.000€

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: ND

Caracterización conductual y farmacológica de modelos murinos de sobreexpresión del gen NTRK3 en el trastorno de pánico y los trastornos fóbicos

Ministerio de Ciencia y Tecnología. Referencia: SAF2001-1231

Entidades participantes:

2001-2004

Cuantía de la subvención: 82.939,67€

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: ND

Sobreexpresión y haploinsuficiencia de Dyrk1A (minibrain) en el retraso mental y el déficit de atención/hiperactividad

Fundació La Marató de TV3

Entidades participantes:

2001 – 2003

Cuantía de la subvención: 57.320,04€

I.P.- **Mariona Arbonés**

Número de investigadores participantes: ND

Implication of Dyrk1A (Minibrain) in learning deficits associated with Down syndrome and their neuromorphological correlates: morphological and chemical characteristics of the pyramidal neuron of the cerebral cortex.

Fundación Jérôme Lejeune. Referencia: 03/3639

Entidades participantes:

2000-2003

Cuantía de la subvención: 23.000€

I.P.- **Xavier Estivill/Mara Dierssen Sotos**

Número de investigadores participantes: ND

Caracterització de BACE2, una possible beta secretasa de APP: generació d'un transgènic de sobreexpressió de BACE2 com un model de malaltia d'Alzheimer

Fundació La Caixa

Cuantía de la subvención: 87.266,91€

Entidades participantes:

2000-2003

I.P.- **Xavier Estivill Pallejà**

Número de investigadores participantes: ND

Validación de modelos murinos de sobreexpresión génica en el cromosoma 16 murino como modelos de neurodegeneración y aproximaciones farmacológicas mediante oligonucleótidos antisentido.

Ministerio de Sanidad FIS. Referencia: 00/0795

Entidades participantes:

2000-2002

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: ND

Desenvolupament i caracterització de models murins de sobreexpressió de gens continguts en la mutació genòmica DUP25, implicada en trastorns de ansietat (pànic).

Fundació La Marató de TV3

Entidades participantes:

1999-2002

I.P.- **Xavier Estivill Pallejà**

Número de investigadores participantes: ND

Estudio genéticos moleculares y funcionales del síndrome de Down y del trastorno de pánico/ansiedad.

Ministerio de educación y ciencia. Referencia: SAF99-0092-C02-01

Entidades participantes: ND

1999-2002

I.P.- **Xavier Estivill Palleja**

Número de investigadores participantes: ND

Modelos murinos de síndrome de Down: caracterización neurológica de transgénicos de sobreexpresión y knockouts de Mnb y Dscr1

Fundación Marcelino Botín

Entidades participantes: ND

1999-2000

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: ND

Murine models for Down syndrome. Development and functional analysis of mouse models for human chromosome 21 genes involved in Down syndrome.

European Comission. Referencia: CEC/BIOMED2 BMH4-CT98-3039

Entidades participantes: ND

1998-2001

I.P.- **Xavier Estivill Pallejà**

Número de investigadores participantes: ND

Estudio de la función y expresión de nuevos genes del cromosoma 21: desarrollo de animales transgénicos para el estudio del síndrome de Down.

Ministerio de educación y ciencia. Referencia: DGCYT PM95-0106-CO2-01

Entidades participantes: ND

1996-1999

I.P.- **Xavier Estivill Pallejà**

Número de investigadores participantes: ND

Influencia de los factores ambientales sobre la función cerebral en animales no seleccionados y con alteraciones genéticas del desarrollo: un análisis funcional, neuroquímico y ultraestructural

Fundación Ramón Areces

Entidades participantes: ND

1995-1998

I.P.- **Jesús Flórez Beledo**

Número de investigadores participantes: ND

Trisomía 21 (síndrome de Down): Estudio neurobiológico e inmunológico y estrategias terapéuticas en un modelo murino, la trisomía 16 parcial

Ministerio de educación y ciencia. Referencia: DGCYT PB94-1063-C02-01

Entidades participantes: ND

1995-1998

I.P.- **Jesús Flórez Beledo**

Número de investigadores participantes: ND

Unidad de Investigación sobre el desarrollo y el envejecimiento: biología, conducta y educación

Fundación Marcelino Botín

Entidades participantes: ND

1995-1997

I.P.- **Jesús Flórez Beledo**

Número de investigadores participantes: ND

Funding for dissemination activities, networks and congresses

Congreso Bienal Sociedad Española de Neurociencias

MINECO

Cuantía de la subvención: 12.000€

I.P.- **Mara Dierssen Sotos**

Congreso FENS 2012

SAF2012-05895-E

Cuantía de la subvención: 80.000€

I.P.- **Juan Lerma/Mara Dierssen Sotos**

Brain awareness week 2010

FENS

01-Ene-2010

Cuantía de la subvención: 1.000€

Feria Científica: Las Ilusiones del Cerebro

FECYT

01-Jun-2010 31-DIC-2010

Cuantía de la subvención: 14.000€

I.P.- **Mara Dierssen Sotos**

Setmana del Cervell 2010
Institut de Cultura de Barcelona (ICUB). Ajuntament de Barcelona
01-Jun-2010 31-DIC-2010 Quantía de la subvención: 9.000€
I.P.- **Mara Dierssen Sotos**

BCNBRAIN
Actuacions En L'àmbit De La Divulgació Científica (ACDC) 2010
01-Ago-2010 31-DIC-2010 Quantía de la subvención: 8.000€
I.P.-**Mara Dierssen Sotos**

XIII Congreso Bienal De La Sociedad Española De Neurociencia
SAF2009-05895-E Quantía de la subvención: 15.000€
I.P.-**Mara Dierssen Sotos**

Fira Científica: Les il·lusions del cervell.
Institut de Cultura de Barcelona (ICUB). Ajuntament de Barcelona
01-Jun-2009 31-DIC-2009 Quantía de la subvención: 8.000€
I.P.- **Mara Dierssen Sotos**

Feria Científica: Las Ilusiones del Cerebro
FECYT
01-Jun-2009 31-DIC-2009 Quantía de la subvención: 15.000€
I.P.- Mavi Sánchez Vives

Scientific Meeting on Down Syndrome: Research, Clinics and Education. "Down syndrome a multidisciplinary perspective"
Fundación Jérôme Lejeune
17-DIC-2008 12-FEB-2009 Quantía de la subvención: 13.000€
I.P.- **Mara Dierssen Sotos**

Art en els límits del cervell.
Institut de Cultura de Barcelona (ICUB). Ajuntament de Barcelona
01-ENE-2008 31-DIC-2008 Quantía de la subvención: 3.000€
I.P.- **Mara Dierssen Sotos**

Arte en los limites del cerebro: un juego de sensación, percepción y creación
Fundacion Española para la Ciencia y la Tecnología. (FECYT)
01-ENE-2008 31-DIC-2008 Quantía de la subvención: 6.000€
I.P.- **Mara Dierssen Sotos**

Identificació i caracterització de noves dianes terapèutiques en malalties neurològiques i psiquiàtriques.

Area de Neurofarmacología. ICIN
Entidades participantes: ND
01-ENE-2005 31-DIC-2008
IP: Mara Dierssen
Número de investigadores participantes: ND

Investigación en red de enfermedades neurológicas
Instituto de Salud Carlos III (C03/06)
Entidades participantes: ND
2003-2006 Quantía de la subvención: 30.849,02€
I.P.- **Mara Dierssen Sotos**
Número de investigadores participantes: ND

Red de Centros de Genética Clínica y Molecular "Integración de la Investigación Clínica, Molecular y Epidemiológica en Genética"

Instituto de Salud Carlos III FIS. Redes Temáticas de Investigación Cooperativa

Entidades participantes: ND

2003-2005

Cuantía de la subvención: 40.100€

I.P.- **Luis Pérez-Jurado**

Número de investigadores participantes: ND

Models animals d'enfermetat relacionada amb el sistema nerviós central

DURSI Referencia: 2003 XT / 00093

Entidades participantes: ND

2003-2005

Cuantía de la subvención: 12.000€

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: ND

Xarxa temàtica de models murins d'enfermetat del SNC

CIRIT Referencia: 2000XT/00083

Entidades participantes: ND

I.P.- **Mara Dierssen Sotos**

Número de investigadores participantes: ND

7th Annual Meeting of the International Behavioural and Neural Genetics Society

Agencia de gestió d'ajuts universitaris (AGAUR)

Referencia: 2005ARCS100104

28-ABR-2005 31-DIC-2005

Cuantía de la subvención: 2.000€

I.P.- **Mara Dierssen Sotos**

Congreso IBANGS

International Behavioural and Neural Genetics Society (IBANGS)

01-ENE-2005 31-DIC-2008

Cuantía de la subvención:

23.829,19€

I.P.- **Mara Dierssen Sotos**

Sociedad Española de Neurociencia (SENC)

01-ENE-2005 31-DIC-2008

Cuantía de la subvención: 1.200€

I.P.- **Mara Dierssen Sotos**

The Role of the Cerebral Cortex in Cognitive Ability: what we know and where we go

Fundación Jérôme Lejeune

2004

Cuantía de la subvención: 3.000€

I.P.- **Mara Dierssen Sotos**

IBANGS Annual Meeting Support

National Institute of Health- National Institute on Alcohol Abuse and Alcoholism (NIH-NIAAA)

2002-2006

I.P.- **John Crabbe-Mara Dierssen Sotos**

International Meeting on Chromosome 21 and Down syndrome

Fundación Jérôme Lejeune

2002

I.P.- **Mara Dierssen Sotos**

International Meeting on Chromosome 21 and Down syndrome

Real Patronato de Atención a la Discapacidad

2002

I.P.- **Mara Dierssen Sotos**

International Meeting on Chromosome 21 and Down syndrome
National Institute of Health-National Institute of Allergy and Infectious Diseases (NIH-
NIAAD)

2002

I.P.- **Mara Dierssen Sotos**

International Meeting on Chromosome 21 and Down syndrome
MICYT Acciones Especiales

2002

I.P.- **Mara Dierssen Sotos**

Societies (selected)

2017 President of the Trisomy 21 Research Society (www.t21rs.org)
2013-2015 President of the Spanish Neuroscience Society
2014 Member of the Academia Europaea
2014- Chair of the Woman in Neuroscience Committee of the Society for
Neuroscience
2014- Member of the “Woman in Science” Commission of the Catalan
Government (Comissió Dona I Ciència)
2013- Member of the Professional Development Committee of the Society for
Neuroscience
2013- Member of the Rigor in Science Committee of the Society for
Neuroscience
2010 - 2012 Executive Committee Member of FENS (Federation of European
Neuroscience Societies)
2010 - Member of EDAB (European DANA Alliance for the Brain)
2010 - Committee Member of COSCE (Confederation of Spanish Science
Societies)
2008 - Member of Barcelona Science Culture Council
2007 - 2009 Vice-president Spanish Society of Neuroscience
2005 - Member of Barcelona Culture Institute Board of Directors
2003 - 2006 President International Behavioural and Neural Genetics Society
2002 - Member of the Council of FENS (Federation of Neuroscience
Association Societies)

Technology Transfer

Patent: Transgenic mice and overexpression model of gene NTRK3 (TRKC) based thereon for the study and monitoring of treatments of anxiety, depression and related psychiatric diseases. WO 01/06848 A1 and P9901674

Patent: Compounds for the treatment of neurodegenerative diseases, P201130033

Exploitation License 2008-2018 “Mouse/Rat immobilization system”. PANLAB/Harvard: 6% royalties

Exploitation License 2008-2018 “Electrified radial arm maze”. PANLAB/Harvard: 6% royalties

Agreement (2018-): Development of a commercial EGCG formula (Font-Up) in collaboration with Grand Fontaine Laboratories

Method and sonification software and system adaptation of the scalp EEG headsets (Technology Readiness Levels, TRLs, 2-3)

Agreement with ORDESA Laboratories for the development and testing of new nutraceutical products 2015-2020

Agreement with PROUS Laboratories for testing new products for neurodegenerative diseases 2013-

Agreement with Ordesa, SA Ministerio de Industria Universidad de Cantabria: Influencia de los ácidos grasos poliinsaturados en el desarrollo cerebral 1996-1999
I.P.- Miguel García-Fuentes

Contracts

Chronic effects of JRP655 for Alzheimer's like defects of cognition

PROUS

Entidades participantes: CRG

2013-2015

Cuantía de la subvención: 20.290€

I.P.- **Mara Dierssen Sotos**

Acute effects of JRP655 in a mouse model for Fragil X Syndrome (FXS)

PROUS

Entidades participantes: CRG

2013-2015

Cuantía de la subvención: 8.333€

I.P.- **Mara Dierssen Sotos**

Scientific Advisory Boards/Evaluation panels

Panels: ANEP, European Research Council, Human Brain Project, ESF College of Expert Reviewers, LonDownS Consortium (Wellcome Trust, UK), European Mouse Mutant Archive (EMMA), Spanish Ministry, ANR-France, Finland Science Foundation, National Polish Science Foundation Panel Expert for European Union (FP6 Call), Scientific evaluation panel of AGAUR (Autonomous Government of Catalonia), Scientific evaluation panel of Consejo Nacional de Ciencia y Tecnología of Argentina (CONCYT) and Sistema Nacional de Ciencia y Tecnología –SINCYT, Scientific evaluation panel of the National Evaluation Agency, Spanish Ministry of Education and Science, Scientific evaluation panel of the Instituto Carlos III, Spanish Ministry of Health

SAB Institut Paris-Saclay (France), Strasbourg (France), Institut Guttman, Fundació Sant Joan de Déu, Barcelona (Spain) 2WAYS, EU-Fundació Catalana per la Recerca, Barcelona (Spain)

Scientific Council: Jerome Lejeune Foundation, Paris (France), Fundació Catalana Síndrome de Down Barcelona (Spain), Down España (Spain) Federación Española de Enfermedades Raras (Spain), Barcelona Science Council Barcelona (Spain) Fundació Bofill (Spain), DANA Alliances Europe

Editorial activity

Editorial Board of Acta Neuropathologica, Associate Editor Genes, Brain and Behaviour, Reviewer Editor Frontiers in Neurosciences, Reviewer Editor Frontiers Genetics of Complex Traits, Section Editor Amino Acids, Senior Editor Down Syndrome Research and Practice, Associate Editor, BMC Neuroscience

Reviewer “ad hoc” for more than 25 international journals (Nature Neuroscience, Journal of Neuroscience, PNAS, PlosONE, Human Molecular Genetics, Elife, Cerebral Cortex, Brain etc.)

Teaching Activity (Selected)

Assistant Professor University of Cantabria

Professor of the University Ramón Llull

Professor of the Master in Neurociencias, University of Barcelona-University Pompeu Fabra

Professor of Cellular and Molecular Pathology, University Pompeu Fabra

Professor of the Master in Neurociencias, of the Autonomous University of Barcelona

Professor of the PhD Program in Health and Life Sciences. Genetics and Disease

Professor of the International Postgraduate Program, Life and Health Sciences, Universidade do Minho, Instituto de Investigação em Ciências da Vida e Saúde, Braga, Portugal

Professor of the PENS/Blackwell International summer school Stress, Drug Addiction and Eating Disorders, Dubrovnick

European Neuropathology Course (Organizer). Genomic Regulation Center. 2007

Mouse Phenotyping Course (Organizer). Master in Science and Laboratory Animal Welfare. Autonomous University of Barcelona. Government of Catalonia. 2007

1st Stereology Course (Organizer). Genomic Regulation Center. 2007

EMBO International training course, Montevideo, Uruguay. 2005-2007

Summer Neuroscience Course. University of Basque Country. San Sebastián 2007

Summer Course El Escorial, Autonomous University of Madrid, Spain, 2006

FENS Hertie Winter School. Kitzbühel, Austria, 2004

Summer International Course. Fòrum de las Culturas. Pompeu Fabra University, Barcelona, Spain 2004

Master de Comunicació Científica Pompeu Fabra University

PhD Program in Neurosciences, Autonomous University of Barcelona. Biochemistry and Molecular Biology Program and Psychobiology Department Program

PhD Program in Health and Life Sciences. Pompeu Fabra University, Barcelona

Pregraduate Course “Molecular Pathology”. Pompeu Fabra University, Barcelona

Doctorate Course UAM-Centro Nacional de Biotecnología, Madrid, Spain

Graduate Course (Psychophysiology, Professor in charge), Ramón Llull University

Doctoral Theses

1. **Nuria M. Vivas Sabido**. (PhD 1993) Acción de la tacrina sobre el deterioro cognitivo durante el envejecimiento: influencia del sistema beta-adrenérgico. Universidad Autónoma de Barcelona
2. **Carmela Baamonde Calzada** (PhD 1995) Efecto protector de cambios ambientales selectivos postnatales sobre las alteraciones cognitivas asociadas al envejecimiento: correlaciones funcionales neuroquímicas y neuromorfológicas Universidad de Cantabria
3. **Salvador García Calatayud** (PhD 1994) Influencia de una dieta de composición variable en ácidos grasos poliinsaturados en el periodo perinatal sobre diferentes aspectos del desarrollo cerebral Co-supervisor: Miguel García-Fuentes Universidad de Cantabria

4. **Iria Flavia Vallina López-Dóriga** (PhD 1996) Caracterización conductual y neuroquímica de un modelo murino de Síndrome de Down (Ts65Dn) Universidad de Cantabria
5. **Carmen Martínez-Cué** (PhD 2001) Disminución de los déficits cognitivos de modelos murinos de desarrollo patológico mediante programas de estimulación temprana Universidad de Cantabria
6. **X. Altafaj** (PhD 2003). Generation and characterization of transgenic Dyrk1A mice Co-supervisor: Dr. C. Fillat, E. Marti University of Barcelona
7. **M. Martínez de Lagrán** (PhD 2006). Neurodegenerative processes in Dyrk1A mouse models. University of Barcelona **Doctorate Award** 2006
8. **Ignasi Sahún** (PhD 2006). Characterization of transgenic NTRK3 mice as model of panic disorder. Autonomous University of Barcelona
9. **Amador-Arjona A.** (PhD 2008). Susceptibility to stress in a mouse model of panic disorder. University of Barcelona
10. **Arqué G.** (PhD 2008). Role of Dyrk1A in CNS development: implications in Down syndrome. University of Barcelona
11. **Gallego X.** (PhD 2008). NTRK3 as genetic interface in anxiety and drug abuse. University of Barcelona
12. **Azcona G.** (PhD 2009). Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Universidad del País Vasco, Campus de Lejona
13. **Obradors C.** (PhD 2011). Role of TrkC isoforms dysregulation in CNS development. University of Barcelona
14. **Molas S.** (PhD 2012). Nicotine addiction phenotypes in a BAC transgenic mouse model overexpressing the CHRNA5/A3/B4 genomic cluster. University Pompeu Fabra
15. **D'Amico D.** (PhD 2013) Fear memories in TgNtrk3 mice, a model of panic disorder. University Pompeu Fabra
16. **Pons Espinal M.** (PhD 2013) Role of DYRK1A in hippocampal neuroplasticity: implications for Down syndrome University Pompeu Fabra
17. **Silvina Catuara.** Neuroplasticity-targeted therapy for Down syndrome: a translational approach. Cum Laude, UPF 2016
18. **Laura Xicota.** ER-beta receptors (ER- β) as therapeutic targets for the improvement of cognitive performance in diseases leading to intellectual disability. Cum Laude, UPF 2016
19. **Jose Antonio Espinosa.** Development of new computational methods for comparison and analysis of longitudinal data in mouse models of addiction, Cum Laude, UPF 2016
20. **Marta Fructuoso.** Compulsive food seeking behavior in intellectual disability. Cum Laude, University of Barcelona 2017. Selected for **Extraordinary Award**
21. **Marcos Quevedo.** Neural correlates of conscious perception in epilepsy patients. Cum Laude, UPF 2017
22. **Linus Manubens.** Modelling the effect of DYRK1A over-expression on neuronal structure and connectivity of Ts65Dn, a Down syndrome mouse model. Cum Laude, UPF 2018
23. **Mireia Ortega.** Elucidation of the mechanism of action of EGCG on the cognitive phenotype in TgDyrk1A Down Syndrome mice model. Cum Laude, UPF 2018

Master Theses

1. Antolin B. (Master Thesis 2007). Pompeu Fabra University. "Effect of environmental enrichment on adult neurogenesis in a Dyrk1A overexpressing mice"
2. Pinacho R. (master Thesis 2008). Pompeu Fabra University. "Characterization of neurogenesis in a murine model overexpressing Dyrk1A (TgDyrk1A)"

3. Trutzel A. (Master Thesis 2008). University of Heidelberg. "Implication of, BACE2 a candidate gene for Down syndrome, in Alzheimer's type pathology".
4. Spadoni O. (Master Thesis 2009). University of Bologna "Understanding the impact of panic attacks on brain systems involved in the pathophysiology of panic disorder"
5. Aliagas S. (Master Thesis 2010). University of Barcelona. "Study of the role of DREAM on neuritogenesis"
6. Vila G. (Master Thesis 2010) University of Barcelona. "Synaptic plasticity in a mouse model of nicotine dependence".
7. Vilaro M. (Master Thesis 2010) University of Barcelona. Characterization of the cerebral cortex of the adult murine model of anxiety and panic disorder
8. Clusella S. (Master Thesis 2010) University of Barcelona. "T" maze as a tool to validate the disparity potential, an endophenotype of murine models of schizophrenia
9. Fernandez Vargas I. (Master Thesis 2010) University of Barcelona. "Development of Bioinformatics tools for longitudinal phenotypic analysis. Application to complex disorders"
10. Leo Pascual. (Master Thesis 2010) University of Barcelona. Cerebellar phenotypes in a mouse model of Down syndrome
11. Reis Faleiro M. (Master Thesis 2011). Stony brook University, NY "Overexpression Of Dyrk1a In The Olfactory Bulb In Mice Model Is Involved In Olfactory Impairment Of Down Syndrome Individuals"
12. Güell Bosch J (Master Thesis 2012) University of Barcelona. Overexpression of the human CHRNA5/A3/B4 cluster alters hippocampal structural plasticity
13. Sara Padrell (Master Thesis 2012) University of Barcelona. "Characterization of the PTPR-TrkC pathway: role of TrkC as a synaptogenic molecule in the TgNTRK3 mouse model"
14. Aida Regi (Master Thesis 2012) University Politechnic of Catalunya. "New biocomputational tools for the analysis of behavior"
15. Victoria Brugada (Graduate Thesis 2012) University Pompeu Fabra. Brain morphological differences in Fragile X Syndrome mouse model
16. Sala J. (Graduate Thesis 2013) University of Barcelona. "Activation of GABAergic cells upon acute nicotine administration"
17. Conejo Gonzalez C. (Undergraduate student 2013) University Pompeu Fabra. "Influence of odour on feeding behaviour and nutrient decision-making"
18. Bautista Perpinya M. (Undergraduate student 2013) Maastricht University. "Appetitive odors modulate feeding patterns of highly-palatable foods in C57BL/6 mice"
19. Blasco Perez B. (Graduate Thesis 2013) University of Barcelona.
20. Freixas Brosa R. ((Master Thesis 2013). University Pompeu Fabra. "Alzheimer's disease biomarkers in Down syndrome"
21. Alemany González M. (Master Thesis 2014) "Study of therapeutic effect of new environmental and pharmacological targets in Down syndrome murine models"
22. C. *Obradors* (DEA 2007). Role of NTRK3 dysregulation in CNS development. University of Barcelona
23. B. *Antolin* (Master 2007). Environmental enrichment in Down syndrome mouse models. Pompeu Fabra University
24. A. *Trutzel* (Master Thesis 2007). Implication of, BACE2 a candidate gene for Down syndrome, in Alzheimer's type pathology and characterization of the neuropathological and cognitive effects of cytotoxic protofibrils from peptides derived of natural amyloid proteins in AD mouse models. University of Heidelberg
25. A. *Amador-Arjona* (DEA 2005). Susceptibility to stress in a mouse model of panic disorder. University of Barcelona
26. G. *Arqué* (DEA 2005). Role of Dyrk1A in CNS development: implications in Down syndrome. University of Barcelona

27. *X. Gallego* (DEA 2005). NTRK3 as genetic interface in anxiety and drug abuse. University of Barcelona
28. *I. Sahún* (DEA 2004). Characterization of transgenic NTRK3 mice. Autonomous University of Barcelona
29. *M. Martínez de Lagrán* (DEA 2003). Phenotypic characterization of Dyrk1A models. University of Barcelona

Professional Careers of Former Dierssen Students (only since 2014)

Postdoctoral fellows

Actual position

Thomas Gener (France, 2011- 15).	Postdoc in Computational Neuroscience at IMIM Hospital del Mar
Monica Santos (Portugal, 2011-15)	Junior Group Leader, Otto-von-Guericke-Universität, Magdeburg, Germany
Ricardo Gómez (Spain, Juan de la Cierva 2015-2016)	Postdoc associate in computational Neuroscience in La Laguna
Ruggero Gerolamo (Italy, 2016-2017)	Postdoc Theoretical Neuroscience at Institut de Biologie of Ecole Normale Superior, Paris

Predocctoral Students

Actual position

Silvina Catuara (Argentina, FPI, 2011-2015).	Jansen Pharmaceutical, Paris, France
Jose Antonio Espinosa (Spain, FPU Catalan Government fellow 2012-2015)	Junior postdoc at CRG
Laura Xicota (Spain, 2011-2016)	Postdoctoral researcher Institut du Cerveau et de la Moelle épinière CNRS, Paris
Marcos Quevedo (México, Shared PhD with Rodrigo Rocamora (Hospital del Mar), CONACYT fellow, 2014-2017)	Neurologist, Institut Dexeus
Linus Manubens (Spain, PhD FI fellowship 2013-2018)	Junior postdoc at IMIM
Mireia Ortega (Spain, PhD Severo Ochoa fellowship 2014-2018)	Lab manager at IDIBAPS, Barcelona
Marta Fructuoso (Spain, CRG fellow, 2012-2017)	Postdoc at ICM, Paris Institute for Brain and Spinal Cord, Paris
Marcin Gorny (Poland, Severo Ochoa fellowship 2016-2017)	Hard Game, Knox Media Hub, SL
Jordi Sala (Spain, 2016-2017).	University of Vic
Ibrahim Tastekin (Turkey, 2016-2018)	Champalimaud Neuroscience Programme, Portugal
Davide D'Amico (Italy, 2011-2014)	CEO Z-Clinics

Organization of International Meetings (selected last 10 years)

- Chair VII Forum of the Federation of European Neurosciences Societies, Barcelona 2012 (7.000 attendees)
- Chair Biennial Meeting Spanish Neuroscience Society, Granada 2015
- Chair European Down Syndrome Consortium, ECNP. Brussels, 2014
- Program Committee of the Cajal Winter Conferences, Salamanca 2014

Program Committee Expert Workshop on the Biology of Chromosome 21 Washington 2013
Chair TEDx BCN Deciphering the mind codes, Barcelona 2012
Chair Principles of information processing in neural systems: how mind emerges from brain. B-Debates, Barcelona 2012
Chair Program Committee of the Jérôme Lejeune-International Conference. Paris, 2011.
Chair Organizing Committee Down Syndrome Research Meeting. Down syndrome Research and Treatment Foundation, San Diego, USA, 2010
Chair Organizing Committee symposium "Down Syndrome: A multidisciplinary Perspective". Society for Neuroscience 2010
Chair Organizing Committee "Congreso bianual de la Sociedad Española de Neurociencias" (SENC). Tarragona, Septiembre 2009.
Chair Organizing Committee symposium "Down Syndrome: A multidisciplinary Perspective". Diciembre 2008
Program Committee Expert Workshop on the Biology of Chromosome 21 Genes: Towards Gene-phenotype Correlations in Down syndrome. Washington 2007
Symposium organizer Spanish Society of Neurosciences, Valencia, Spain 2007
Symposium organizer Federation of European Neurosciences Societies Forum Vienna, Austria 2006
Organizer of the International Neurosciences Seminar Foundation Duques de Soria - Spanish Neurosciences Society, Soria, Spain 2006
Organizer of the VII Annual Meeting of the International Behavioural and Neural Genetics Society, Sitges, Spain 2005

Invited Lectures

2014 Plenary Lecture. Meeting of the French Society of Neuroscience, Montpellier Neuroscience Institute CNR (National Research Council); University of Valencia, IPMC - CNRS Nice; CaixaForum Madrid; Institut de Recerca Germans Trias i Pujol (IGTP); V Jornadas Red Olfativa Española, Asturias; Scuola Normale, University of Pisa; Universidad Mayor Chile; Biotech Annual Congress, BAC2014; FENS, Milan 2014; Gordon Research Conference on the Neurobiology of Brain Disorders; Instituto Cajal, Madrid, E-Rare Symposium, Rome

2015 Plenary Lecture 12th Polish Neuroscience Society; Plenary Lecture 17th International Fragile X and Early-Onset Cognitive Disorders, Strasbourg; Invited Lecture, Trisomy 21 Research Society, Paris; Gencodys Conference 2015 "Integrative Networks in Intellectual Disability", Crete, Greece; Facultat Biologia (UB), Barcelona; Gender Sensitive Research" 28th ECNP Congress; Minisymposium speaker at Neuroscience 2015, Chicago

2016 Conference-Debate Nature Pub Group Madrid; TEDEX, Amposta; University of Vic; Plenary Lecture, Academia Europaea, Cardiff; European Parliament, Strasbourg; CORBI courses University of A Coruña; UAB, Barcelona; From molecules to systems: neuropathology, Universidad Internacional Menéndez Pelayo;

2017 4th International Seminar on Behavioral Methods, Poland; 29th ECNP Congress, Vienna; Nanyang Technological University, Singapore; Universitat de Lleida; Babraham Institute - EU Life Lecture; V Simposio CERU London; 30th ECNP Congress of Applied and Translational Neuroscience; 42nd FEBS Congress, Israel; FENS regional Meeting, Hungary; Magister Lesson Hospital Universitario Ramón y Cajal,

Madrid; Plenary Lecture II Congreso Nacional de Jóvenes Investigadores en Biomedicina, Valencia; Real Sociedad Menendez Pelayo, Santander

Other (selected)

Plenary Lecture Down syndrome Conference, México (2013)
Seminar Wellcome Trust, Cambridge, UK (2011)
International Conferences Jerome Lejeune Paris (2011)
Seminar Institut Clinique de la Souris (ICS), Université de Strasbourg (2010)
Minisymposium 40th Meeting of the Society for Neuroscience. San Diego, (2010)
MIND Institute, UC Davies, Sacramento, California, USA (2010)
Plenary Lecture, Monod Conferences, Roscoff (2010)
PECB Invited Lectures, Institut d'Investigació Biomèdica de Bellvitge (2009)
Plenary Lecture 5th International meeting on cryptic chromosomal rearrangements in mental retardation and autism. Troina, Italy (2009)
Plenary Lecture University of Padova, Italy (2008)
5th International meeting on cryptic chromosomal rearrangements in mental retardation and autism. Troina, Italy, April 17-18, 2009
University of Padova, Italy, October, 2008
Universidade do Minho, Instituto de Investigação em Ciências da Vida e Saúde, Braga, Portugal 2007, 2010
Expert Workshop on the Biology of Chromosome 21. Washington, 2007.
The Hebrew University, Jerusalem, June 2007.
Plenary lecture First International Conference Synapses-Memory-Drug, Addiction and Pain. University of Toronto, Canada 2006
Invited talk Otto-von-Guericke-Universität Magdeburg, Germany, 2006
Symposium FENS Forum 2006 Vienna, Austria 2006
Invited talk, Society of Biology, University of Barcelona, Spain, 2005
Symposium 5th International Conference on Methods and Techniques in Behavioural Research Wageningen, The Netherlands, 2005
Invited talk 6th Transgenesis Technology Meeting 2005, Barcelona, Spain, 2005

Publications

1. D'Amico D, .. Dierssen M. Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear. **Neuropsychopharmacology**. (2017) 42(2):462-472.
2. Ruiz-Mejias M; ...; Dierssen M. Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex. **The Journal of Neuroscience**. (2016) 36(13):3648-59
3. Espino Gaurch M, ... Dierssen M, Varela-Nieto I, Gasparini P, Palacín M, Nunes V. Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in Age-Related Hearing Loss. **Elife**. 2018 Jan 22; 7. pii: e31511.
4. Espinosa-Carrasco J, ... Dierssen M. Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice. **Addiction Biology** (2018) Jan 10. doi: 10.1111/adb.12595. [Epub ahead of print]

5. Burokas A, ...Dierssen M, Maldonado R. Extinction and reinstatement of an operant responding maintained by food in different models of obesity. **Addict Biol.** 2017 Dec 28. doi: 10.1111/adb.12597. [Epub ahead of print]
6. Fourcade S... Dierssen M, Ferrer I, Villarroya F, Pamplona R, Vaquero A, Portero-Otín M, Pujol A. Loss of SIRT2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance. **Aging Cell.** 2017 Oct 5. doi: 10.1111/accel.12682. [Epub ahead of print]
7. Fructuoso M, ... Dierssen M. Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome. **Free Radic Biol Med.** 2017 114:122-130
8. Gómez-Grau M, ... Dierssen M, Vilageliu L, Grinberg D. New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease. **Science Reports.** 2017 7:41931.
9. Fenoll R, Pujol J, Esteba-Castillo S, de Sola S, Ribas-Vidal N, García-Alba J, Sánchez-Benavides G, Martínez-Vilavella G, Deus J, **Dierssen M**, Novell-Alsina R, de la Torre R. "Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients". **Journal of Alzheimer's Disease.** 2017;57(1):61-70
10. Gómez-Grau M, Albaigès J, Casas J, Auladell C, **Dierssen M**, Vilageliu L, Grinberg D. "New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease". **Scientific Reports.** 2017 Feb 7;7:41931
11. Delabar JM, Allinquant B, Bianchi D, Blumenthal T, Dekker A, Edgin J, O'Bryan J, **Dierssen M**, Potier MC, Wiseman F, Guedj F, Créau N, Reeves R, Gardiner K, Busciglio J. "Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society". **Molecular Syndromology.** 2016 Oct;7(5):251-261.
12. Catuara-Solarz S, Espinosa-Carrasco J, Erb I, Langohr K, Gonzalez JR, Notredame C, **Dierssen M**. "Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome". **eNeuro.** 2016 Nov 8;3(5).
13. Del Hoyo L, Xicota L, Langohr K, Sánchez-Benavides G, de Sola S, Cuenca-Royo A, Rodriguez J, Rodríguez-Morató J, Farré M, **Dierssen M**, de la Torre R. "VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome". **Frontiers in Behavior Neuroscience,** 2016 Oct 17;10:193.

14. D'Amico D, Gener T, de Lagrán MM, Sanchez-Vives MV, Santos M, **Dierssen M**. "Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear". **Neuropsychopharmacology**, 2017 Jan;42(2):462-472.
15. De la Torre R... **Dierssen, M**. "Safety and efficacy of the combination of cognitive training and epigallocatechin-3-gallate for cognitive improvement in adults with Down syndrome: a double-blind randomised controlled trial". **The Lancet Neurology**, (2016); Jul 2016;15(8):801-10 FI 21,896 Q1
16. Ruiz-Mejias, ... **Dierssen, M**. "Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex" **Journal of Neuroscience** 36(13): 3648-3777 (2016). FI 6,344 Q1
17. Sanchez-Mut, J.V., Heyn, H., Vidal, E., Moran, S., Sayols, S., Delgado-Morales, R., Schultz, M.D., Ansoleaga, B., Garcia-Esparcia, P., Pons-Espinal, M., Martínez de Lagran, M, Dopazo, J., Rabano, A., Avila, J., **Dierssen, M**., Lott, I., Ferrer, I., Ecker, J.R., Esteller, M. "Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns" **Transl. Psychiatr.** 6: e718 (2016) FI 4,360 Q1
18. Falsafi, S, **Dierssen, M**, Ghafari, M, Pollak, A, Lubec, G. "Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain" **Amino Acids**. Vol.48: 103-116 (2016) FI 3,653 Q1
19. Catuara-Solarz, S, Espinosa-Carrasco, J, Erb, I, Langohr, K, Notredame, C, Gonzalez, JR., **Dierssen, M**. "Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome" **Front. Behav. Neurosci.** Vol. (2015) FI 4,160 Q1
20. Hoyo LD, Xicota L, Sánchez-Benavides G, Cuenca-Royo A, de Sola S, Langohr K, Fagundo AB, Farré M, **Dierssen M**, de la Torre R. "Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma A beta(42) Concentrations in Down Syndrome Young Adults" **Front. Behav. Neurosci.** Vol.9: 301-0 (2015) FI 4,160 Q1
21. Bofill-De Ros X, Santos M, Vila-Casadesús M, Villanueva E, Andreu N, **Dierssen M**, Fillat C. "Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges" **Bmc Genomics**. Vol.16: 907-0 (2015) FI 4,041 Q1
22. Ballester-Lurbe, B., González-Granero, S., Mocholí, E., Poch, E., García-Manzanares, M., **Dierssen, M**., Pérez-Roger, I., García-Verdugo, J.M., Guasch, R.M., Terrado, J.. "RhoE deficiency alters postnatal subventricular zone

- development and the number of calbindin-expressing neurons in the olfactory bulb of mouse" **Brain Struct. Funct.**. Vol.220: 3113-3130 (2015) FI 4,567 Q1
23. Bartesaghi R, Haydar TF, Delabar JM, **Dierssen M**, Martínez-Cué C, Bianchi DW. "New Perspectives for the Rescue of Cognitive Disability in Down Syndrome" **Journal of Neuroscience**. Vol.35: 13843-13852 (2015) FI 6,747 Q1
24. Solarz, S. C., **Dierssen, M.** "Kinase activity modulation to restore cognitive impairment and prevent neurodegeneration in a mouse model of down's syndrome" **J. Neurochem.**. Vol.134: 195-0 (2015) FI 4,244 Q1
25. Santos M, D'Amico D, **Dierssen M.** "From neural to genetic substrates of panic disorder: Insights from human and mouse studies" **Eur. J. Pharmacol.**. Vol.759: 127-141 (2015) FI 2,684 Q2
26. de Sola, S, de la Torre, R, Sanchez-Benavides, G, Benejam, B, Cuenca-Royo, A, ... **Dierssen, M**, TEDSAD Study Grp. "A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials" **Front. Psychol.**. Vol. (2015) FI 2,843 Q1
27. Weitzdoerfer, R, Toran, N, Subramaniyan, S, Pollak, A, **Dierssen, M**, Lubec, G. "A cluster of protein kinases and phosphatases modulated in fetal Down syndrome (trisomy 21) brain" **Amino Acids**. Vol.47: 1127-1134 (2015) FI 3,653 Q1
28. Brault, V, Romestaing, C, Sahun, I, Karout, Mona, Borel, Christelle, Dembele, Doulaye, Bizot, Jean-Charles, Messaddeq, Nadia, Sharp, Andrew J., Roussel, Damien, Antonarakis, Stylianos E., **Dierssen, Mara**, Herault, Yann. "Locomotor dysfunction and hypotonia in down syndrome mouse models for the hspa13-app region as a consequence of dosage sensitive genes controlling muscular metabolism and mitochondrial function" **Acta Physiol.**. Vol.214: 11-12 (2015) FI 4,251 Q1
29. Brault, Veronique, Duchon, Arnaud, Romestaing, Caroline, Sahun, Ignasi, Pothion, Stephanie, Karout, Mona, Borel, Christelle, Dembele, Doulaye, Bizot, Jean-Charles, Messaddeq, Nadia, Sharp, Andrew J., Roussel, Damien, Antonarakis, Stylianos E., **Dierssen, Mara**, Herault, Yann. "Opposite Phenotypes of Muscle Strength and Locomotor Function in Mouse Models of Partial Trisomy and Monosomy 21 for the Proximal Hspa13-App Region" **PLoS Genet.**. Vol. (2015) FI 8,167 Q1
30. Rodríguez-Morató J, Xicota L, Fitó M, Farré M, **Dierssen M**, de la Torre R. "Potential Role of Olive Oil Phenolic Compounds in the Prevention of Neurodegenerative Diseases" **Molecules**. Vol.20: 4655-4680 (2015) FI 2,095 Q3
31. **Dierssen, M.**, Pujol, J., del Hoyo, L., Blanco-Hinojo, L., de Sola, S., Macià, D., Martínez-Vilavella, G., Amor, M., Deus, J., Rodríguez, J., Farré, M.. "Anomalous

- brain functional connectivity contributing to poor adaptive behavior in Down syndrome" *Cortex*. Vol.64: 148-156 (2015) FI 6,042 Q1
32. Catuara-Solarz S, Espinosa-Carrasco J, Erb I, Langohr K, Notredame C, Gonzalez JR, **Dierssen M**. "Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome." *Front. Behav. Neurosci.*. Vol.9: 330-0 (2015) FI 4,160 Q1
 33. Souchet, B., Guedj, F., Sahún, I., Duchon, A., Daubigney, F., Badel, A., Yanagawa, Y., Barallobre, M.J., **Dierssen, M.**, Yu, E., Herault, Y., Arbones, M., Janel, N., Créau, N., Delabar, J.M.. "Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage" *Neurobiol Dis*. Vol.69: 65-75 (2014) FI 5,202 Q1
 34. Molas S, Gener T, Güell J, Martín M, Ballesteros-Yáñez I, Sanchez-Vives MV, **Dierssen M**. "Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice." *Acta Neuropathol Commun*. Vol.2: 147-0 (2014) FI 0 Q.
 35. Pujol J, Del Hoyo L, Blanco-Hinojo L, de Sola S, Macià D, Martínez-Vilavella G, Amor M, Deus J, Rodríguez J, Farré M, **Dierssen M**, de la Torre R Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome.*Cortex*. 2014 Oct 28; 64C:148-156.
 36. Segura-Puimedon M, Sahún I, Velot E, Dubus P, Borralleras C, Rodrigues AJ, Valero MC, Valverde O, Sousa N, Herault Y, **Dierssen M**, Pérez-Jurado LA, Campuzano V. Heterozygous deletion of the Williams-Beuren syndrome critical interval in mice recapitulates most features of the human disorder. *Human Molecular Genetics*, 2014.
 37. Molas S, **Dierssen M**. The role of nicotinic receptors in shaping and functioning of the glutamatergic system: A window into cognitive pathology. *Neuroscience & Behavioral Reviews*, 2014.
 38. Sahun, Ignasi, Marechal, Damien, Pereira, Patricia Lopes, Nalesso, Valerie, Gruart, Agnes, Delgado Garcia, Jose Maria, Antonarakis, Stylianos E., **Dierssen, Mara**, Herault, Yann. Cognition and Hippocampal Plasticity in the Mouse Is Altered by Monosomy of a Genomic Region Implicated in Down syndrome. *Genetics* 197 (3) 899-912. 201.
 39. Mellström, B., Sahún, I., Ruiz-Nuño, A., Murtra, P., Gomez-Villafuertes, R., Savignac, M., Oliveros, J.C., Gonzalez, P., Kastanauskaite, A., Knafo, S., Zhuo, M., Higuera-Matas, A., Errington, M.L., Maldonado, R., DeFelipe, J., Jefferys, J.G.R., Bliss, T.V.P., **Dierssen, M.**, Naranjo, J.R. DREAM controls the on/off switch of

- specific activity-dependent transcription pathways. *Molecular and Cellular Biology* 34 (5) 877-887. 2014.
40. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, Fitó M, Benejam B, Langohr K, Rodriguez J, Pujadas M, Bizot JC, Cuenca A, Janel N, Catuara S, Covas MI, Blehaut H, Herault Y, Delabar JM, **Dierssen M**. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. *Molecular Nutrition & Food Research* 58(2) 278-288. 2014.
 41. Ballester-Lurbe, B., González-Granero, S., Mocholí, E., Poch, E., García-Manzanares, M., **Dierssen, M.**, Pérez-Roger, I., García-Verdugo, J.M., Guasch, R.M., Terrado, J. RhoE deficiency alters postnatal subventricular zone development and the number of calbindin-expressing neurons in the olfactory bulb of mouse. *Brain Structure and Function* 2014.
 42. Muldoon PP, Jackson K, Perez E, Harenza J, Raisa B, Anwara H, Zaveri NT, Molas S, Maldonado R, **Dierssen M**, Maskos U, McIntosh JM, Miles MF, Chen X, De Biasi M, Damaj MI. The alpha3beta4* nicotinic acetylcholine receptor subtype mediates physical dependence to morphine: mouse and Human studies. *British Journal of Pharmacology*, 2014
 43. Mouton-Liger, F; Sahún I; Collin,T; Lopes Pereira P; Masini D; Thomas S; Paly E; Luillier S; Meme S; Jouhault Q; Bennaï S; Beloeil J-C; Bizot, J-C; Herault, Y; **Dierssen, M**; Creau N Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: Implications for Down syndrome. *Neurobiol Dis.* 63:92-106, 2014
 44. Del Pino I, García-Frigola C, Dehorter N, Brotons-Mas JR, Alvarez-Salvado E, Martínez de Lagrán M, Ciceri G, Gabaldón MV, Moratal D, **Dierssen M**, Canals S, Marín O, Rico B. Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. *Neuron.* 79(6):1152-68, 2013
 45. Santos M, D'Amico D, Spadoni O, Amador-Arjona A, Stork O, **Dierssen M**. Hippocampal Hyperexcitability Underlies Enhanced Fear Memories in TgNTRK3, a Panic Disorder Mouse Model. *J Neurosci.* 33(38):15259-71, 2013
 46. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, Fitó M, Benejam B, Langohr K, Rodriguez J, Pujadas M, Bizot JC, Cuenca A, Janel N, Catuara S, Covas MI, Blehaut H, Herault Y, Delabar JM, **Dierssen M**. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. *Mol Nutr Food Res.* 58(2):278-88, 2014
 47. Sanchez-Mut JV, Aso E, Panayotis N, Lott I, **Dierssen M**, Rabano A, Urdinguio RG, Fernandez AF, Astudillo A, Martin-Subero JI, Balint B, Fraga MF, Gomez A,

- Gurnot C, Roux JC, Avila J, Hensch TK, Ferrer I, Esteller M. DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease. *Brain*. 136(Pt 10):3018-27 2014
48. Carrasco P, Jacas J, Sahún I, Muley H, Ramírez S, Puisac B, Mezquita P, Pié J, **Dierssen M**, Casals N. Carnitine palmitoyltransferase 1C deficiency causes motor impairment and hypoactivity. *Behav Brain Res*. 256:291-7, 2013.
 49. Pons-Espinal M, Martinez de Lagran M, **Dierssen M**. Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. *Neurobiol Dis*. 60:18-31, 2013. Recommended by F1000
 50. Stefanos GC, Soppa U, **Dierssen M** Becker W. The Down syndrome-related proteins DYRK1A and RCAN1 attenuate the NGF-induced upregulation of plasminogen activation inhibitor-1 in neurons. *PLoS One*. 8(6):e67470, 2013
 51. Busquets-Garcia, M. Gomis-González, T. Guegan, C. Agustín-Pavón, A. Pastor, R. de la Torre, **M. Dierssen**, R. Maldonado, A. Ozaita, Targeting the endocannabinoid system in the treatment of fragile X syndrome. *Nature Medicine*, 9(5):603-7, 2013 Recommended by F1000
 52. Arque G, Casanovas A, **Dierssen M**. Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome. *PLoS One*. 2013;8(1):e54285.
 53. Llorente-Folch I, Sahún I, Contreras L, Casarejos MJ, Grau JM, Saheki T, Mena MA, Satrustegui J, **Dierssen M**, Pardo B. AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. *J Neurochem*. 124(3): 347-62, 2013.
 54. **Dierssen M**. A commentary on: Overexpression of Dyrk1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. *Exp Neurol*. 2013 Apr 6;247C:110-112. Clave Editorial Material. IF: 4.645.
 55. Pons-Espinal M., De Lagran M.M., **Dierssen M**. Functional implications of hippocampal adult neurogenesis in intellectual disabilities. *Amino Acids* 45 (1) , pp. 113-131 Jul 2013. Clave R. IF: 3.914.
 56. Stefanos G.C., Soppa U., **Dierssen M.**, Becker W. NGF Upregulates the Plasminogen Activation Inhibitor-1 in Neurons via the Calcineurin/NFAT Pathway and the Down Syndrome-Related Proteins DYRK1A and RCAN1 Attenuate This Effect. *PLoS ONE* 8(6) e67470 doi: 10.1371/journal.pone.0067470. 25 Jun 2013. Clave A. IF: 3.730.
 57. Altafaj X., Martin E.D., Ortiz-Abalia J., Valderrama A., Lao-Peregrin C., **Dierssen M.**, Fillat C. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates

- hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. *Neurobiology of Disease* 52 pp. 117-127. Abr 2013. Clave A. IF: 5.624.
58. **Dierssen M.** Down syndrome: The brain in trisomic mode. *Nature Reviews Neuroscience* 13:12. 2012. IF: 31.673. Clave: A.
59. Garriga-Canut M., Agustin-Pavon C., Herrmann F., Sanchez A., **Dierssen M.**, Fillat C., Isalan M. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. *Proceedings of the National Academy of Sciences of the United States of America* 109:45. 2012. IF: 9.737. Clave: A.
60. Martinez De Lagran M., Benavides-Piccione R., Ballesteros-Yanez I., Calvo M., Morales M., Fillat C., Defelipe J., Ramakers G.J.A., **Dierssen M.** Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. *Cerebral Cortex* 22:12. 2012. IF: 6.828. Clave: A.
61. Carrasco P., Sahun I., McDonald J., Ramirez S., Jacas J., Gratacos E., Sierra A.Y., Serra D., Herrero L., Acker-Palmer A., Hegardt F.G., **Dierssen M.**, Casals N. Ceramide levels regulated by carnitine palmitoyltransferase 1C control dendritic spine maturation and cognition. *Journal of Biological Chemistry* 287:25. 2012. IF: 4.651. Clave: A.
62. de la Torre R., **Dierssen M.** Therapeutic approaches in the improvement of cognitive performance in Down syndrome: Past, present, and future. *Progress in Brain Research* 197. 2012. IF: 4.191. Clave: A.
63. Gallego X., Molas S., Amador-Arjona A., Marks M.J., Robles N., Murtra P., Armengol L., Fernandez-Montes R.D., Gratacos M., Pumarola M., Cabrera R., Maldonado R., Sabria J., Estivill X., **Dierssen M.** Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. *Amino Acids* 43:2. 2012. IF: 3.914. Clave: A.
64. Vinals X., Molas S., Gallego X., Fernandez-Montes R.D., Robledo P., **Dierssen M.**, Maldonado R. Overexpression of $\alpha 3/\alpha 5/\beta 4$ nicotinic receptor subunits modifies impulsive-like behavior. *Drug and Alcohol Dependence* 122:3. 2012. IF: 3.141. Clave: A.
65. Gallego X., Ruiz-Medina J., Valverde O., Molas S., Robles N., Sabria J., Crabbe J.C., **Dierssen M.** Transgenic over expression of nicotinic receptor alpha 5, alpha 3, and beta 4 subunit genes reduces ethanol intake in mice. *Alcohol* 46:3. 2012. IF: 2.255. Clave: A.
66. Mercader J.M., Gonzalez J.R., Lozano J.J., Bak M., Kauppinen S., Sumoy L., **Dierssen M.**, Fernandez-Aranda F., Visa J., Gratacos M., Estivill X. Aberrant brain microRNA target and miRISC gene expression in the anx/anx anorexia mouse model. *Gene* 497:2. 2012. IF: 2.196. Clave: A.

67. **Dierssen M**, Fedrizzi L, Gomez-Villafuertes R, de Lagran MM, Gutierrez-Adan A, Sahún I, Pintado B, Oliveros JC, Dopazo XM, Gonzalez P, Brini M, Mellström B, Carafoli E, Naranjo JR. Reduced Mid1 Expression and Delayed Neuromotor Development in daDREAM Transgenic Mice. *Frontiers in Molecular Neuroscience* 5:58. 2012.
68. Teixeira CM, Martín ED, Sahún I, Masachs N, Pujadas LI, Corvelo A, Bosch C, Rossi D, Martinez A, Maldonado R, **Dierssen M** Soriano E Over-expression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder, *Neuropsychopharmacology*, in press I.F. 6.993. Clave: A.
69. Baamonde C, Martínez-Cué C, Flórez J, **Dierssen M**. G protein-associated signal transduction processes are restored after post-weaning environmental enrichment in Ts65Dn, a Down syndrome mouse model. *Developmental Neuroscience*. In press. I.F. = 3.335
70. Mocholí E, Ballester-Lurbe B, Arqué G, Poch E, Peris B, Guerri C, **Dierssen M**, Guasch RM, Terrado J, Pérez-Roger I. RhoE Deficiency Produces Postnatal Lethality, Profound Motor Deficits and Neurodevelopmental Delay in Mice. *PLoS One*. 2011 Apr 28;6(4):e19236. I.F. = 4.351
71. **Dierssen M**, Arqué G, McDonald J, Andreu N, Martínez-Cué C, Flórez J, Fillat C. Behavioral characterization of a mouse model overexpressing DSCR1/ RCAN1. *PlosOne* 6(2):e17010, 2011. Clave: A., I.F. = 4.351
72. Sun Y, **Dierssen M**, Toran N, Pollak DD, Chen WQ, Lubec G. A gel-based proteomic method reveals several protein pathway abnormalities in fetal Down syndrome brain. *J Proteomics*, 74(4):547-57, 2011 Clave: A., I.F. = 3.851
73. Mercader JM, González JR, Lozano J, Bak M, Kauppinen S, Sumoy L, Dierssen M, Fernández-Aranda F, Visa J, Gratacòs M, Estivill X. Aberrant brain miRNA target and miRISC gene expression in the anx/anx anorexia mouse model. Submitted. Clave: A
74. Gardiner K, Herault Y, Lott IT, Antonarakis S, Reeves R, **Dierssen M**. Down Syndrome: From Understanding the Neurobiology to Therapy. *J. Neurosci.* 30(45): 14943-14945, 2010. Clave: R I.F. = 7.178
75. Santos M, Summavielle T, Silva-Fernandes A, Teixeira-Castro A, Duarte-Silva S, Marques F, Martins L, **Dierssen M**, Oliveira P, Sousa N, Maciel P. Monoamine deficits in the brain of Mecp2-null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. *Neuroscience* 170(2):453-67, 2010 Clave: A I.F. = 4.518

76. Azkona G, Levanon D, Groner Y, **Dierssen M**. In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. *Amino Acids*, 39(5):1571-80, 2010 Clave: A I.F. = 3.877
77. Toiber D, Azkona G, Ben-Ari S, Torán N, Soreq H, **Dierssen M** Engineering DYRK1A over-dosage yields Down syndrome-characteristic cortical splicing aberrations. *Neurobiology of Disease*, 40(1):348-59, 2010 Clave: A I.F. = 4.518
78. **Dierssen M**, Lott I Down Syndrome: Neurological Complications and Cognition, *The Lancet Neurology*, 9(6): 623-33, 2010. Clave: R I.F. = 18.126
79. Fillat C, **Dierssen M**, Martínez de Lagrán M, Altafaj X. Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome. *CNS & Neurolog Disord- Drug Targets*, 9(4):429-38, 2010. Clave: R I.F. = 3.571
80. Gallego X, Murtra P, Zamalloa T, Canals JM, Pineda J, Amador-Arjona A, Maldonado R, **Dierssen M**. Increased opioid dependence in a mouse model of panic disorder. *Frontiers in Behavioral Neurosci*, Front Behav Neurosci. 3: 60 2010. Clave: A
81. Botella-López A, Cuchillo-Ibáñez I, Cotrufo T, Su San Mok, Qiao-Xin Li, Barquero M-S, **Dierssen M**, Soriano E Sáez-Valero J, Beta-amyloid controls altered Reelin expression and processing in Alzheimer's disease. *Neurobiol Disease* 37(3): 682-91 2010. Clave: A I.F. = 4.518
82. Heyne A, Kiesselbach C, **Sahún I**, **McDonald J**, Gaiffi M, **Dierssen M**, Wolffgramm J An animal model of compulsive food taking behaviour. *Addiction Biology*, 14, 373–383, 2009 . Clave: A I.F. = 4.728
83. **Azkona G**, **Amador-Arjona A**, **Obradors-Tarragó C**, Varea E, **Arqué G**, **Pinacho R**, Fillat C, de la Luna S, Estivill X, **Dierssen M**. Characterization of a mouse model overexpressing BACE2 reveals a new role for BACE2. *Genes Brain Behav*, 9(2):160-72, 2009. Clave: A I.F. = 3.795
84. **Amador-Arjona A**, Delgado-Morales R, Belda X, Gagliano H, **Gallego X**, Keck ME, Armario A, **Dierssen M**. Susceptibility To Stress In Transgenic Mice Overexpressing TrkC, A Model Of Panic Disorder. *Journal of Psychiatric Research*, 44(3):157-67, 2009 . Clave: A I.F. = 3.723
85. Lopes Pereira P, Magnol L, **Sahún I**, Brault V, Duchon A, Prandini P, Gruart A, Bizot J-C, Chadeaux-Vekemans B, Deutsch S, Trovero F, Delgado-García JM, Antonarakis SE, **Dierssen M**, Herault Y. A new mouse model for the trisomy of the abcg1-u2af1 region reveals the complexity of the combinatorial genetic code of Down syndrome. *Hum. Mol Genet*, 18: 4756-69, 2009. Clave: A I.F. = 7.386

86. **Arqué G, Martínez de Lagrán M**, Arbonés M. L., **Dierssen M**. Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice, *Neurobiology of Disease*, 36: 312-319, 2009. Clave: A I.F. = 4.518
87. **Dierssen M**, Herault, Y, Estivill, X. Aneuploidy: from a Physiological Mechanism of Variance to Down Syndrome *Physiological Reviews*. 89: 887-920, 2009. Clave: R I.F. = 37.726
88. Giralt A, Rodrigo T, Martin ED, González JR, Ceña V, **Dierssen M**, Canals JM, Alberch J, Brain Derived Neurotrophic Factor modulates the severity of cognitive alterations induced by mutant huntingtin through changes in phospholipaseC γ activity and glutamate receptor expression. *Neuroscience*. 18, 158:1234-50, 2009. Clave: A I.F.= 3.292
89. Mercader JM, Lozano JJ, Sumoy L, **Dierssen M**, Visa J, Gratacos M, Estivill X. Hypothalamus transcriptome profile suggests an anorexia-cachexia syndrome in the anx/anx mouse model. *Physiol Genomics*. 12, 35: 341-50, 2008. Clave: A I.F. = 3.931
90. Ortiz-Abalia J, **Sahún I**, Altafaj X, Estivill X, **Dierssen M**, Fillat C. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in a mouse model of Down syndrome. *Am J Hum Genet*. 83: 479-88, 2008. Clave: A I.F. = 12.162
91. X. Altafaj, J. Ortiz-Abalia, M. Fernández, M.C. Potier, J. Laffaire, N. Andreu, **M. Dierssen**, C. González-García, V. Ceña, E. Martí and C. Fillat Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. *Neurobiol Dis*. 32: 377-84, 2008. Clave: A I.F. = 4.518
92. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, Baeza-Raja B, **Martínez de Lagrán M**, Lafuste P, Ruiz-Bonilla V, Jardí M, Gherardi R, Christov C, **Dierssen M**, Carmeliet P, Degen JL, Dewerchin M, Muñoz-Cánoves P. Fibrinogen drives dystrophic muscle fibrosis via a TGF β /alternative macrophage activation pathway. *Genes Dev*. 22: 1747-52, 2008. Clave: A I.F. = 12.075
93. **Arqué G**, Fotaki V, Fernández D, **Martínez de Lagrán M**, Arbonés M.L. **Dierssen M** Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for Dyrk1A. *PLoS ONE* 3: e2575, 2008. Clave: A I.F. = 4.351
94. Pritchard M, Reeves RH, **Dierssen M**, Patterson D, Gardiner KJ. Down syndrome and the genes of human chromosome 21: current knowledge and future potentials. Report on the Expert workshop on the biology of chromosome 21 genes: towards gene-phenotype correlations in Down syndrome. Washington D.C. *Cytogenet Genome Res*. 121: 67-77, 2008. Clave: A I.F. = 1.729

95. Mercader JM, Saus E, Agüera Z, Bayés M, Boni C, Carreras A, Cellini E, de Cid R, **Dierssen M**, Escaramis G, Fernández-Aranda F, Forcano L, González J.R., Gorwood P, Hebebrand J, Hinney AS, Nacmias A, Puig A, Ribasés M, Gratacòs M Estivill X Association of NTRK3 and interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. *Human Mol Genet* 17: 1234-44, 2008. Clave: A I.F. = 7.386
96. Cheon, MS., **Dierssen M**, Kim, SH, Lubec G Protein expression of BACE1, BACE2 and APP in Down syndrome brains. *Amino Acids*. 35: 339-43, 2008 . Clave: A I.F. = 3.877
97. Suelves M, Vidal B, Serrano AL, Tjwa M, Roma J, López-Alemany R, Luttun A, **de Lagrán MM**, Díaz MA, Jardí M, Roig M, **Dierssen M**, Dewerchin M, Carmeliet P, Muñoz-Cánoves P. uPA deficiency exacerbates muscular dystrophy in MDX mice. *J Cell Biol*. 178: 1039-51, 2007. Clave: A I.F. = 9.575
98. **Dierssen M**. Understanding the human brain through mouse models *Genes Brain Behav*, 6: 1-1, 2007. Clave: E I.F. = 3.795
99. Gratacós M., **Sahún I.**, **Gallego X.**, **Amador-Arjona A.**, Estivill X., **Dierssen M.** Candidate genes for panic disorder: insight from human and mouse genetic studies. *Genes Brain Behav*. 6: 2-23. 2007 Clave: A I.F. = 3.795
100. Whittle N, Sartori SB, **Dierssen M**, Lubec G, Singewald N Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. *Pediatrics*. 120: e1465-71, 2007 Clave: A I.F. = 4.687
101. **Sahún I**, Delgado-García JM, **Amador-Arjona A**, Giralt A, Alberch J, **Dierssen M** Gruart A Dissociation between CA3-CA1 synaptic plasticity and associative learning in TgNTRK3 transgenic mice *J. Neurosci*. 27: 2253-60. 2007. Clave: A I.F. = 7.178
102. **Sahún I**, **Gallego X**, Gratacòs M, Murtra P, Trullás R, Maldonado R, Estivill X, **Dierssen M** Differential Responses to Anxiogenic Drugs in a Mouse Model of Panic Disorder As Revealed by Fos immunocytochemistry in Specific Areas of the Fear Circuitry. *Amino Acids* 33: 677-88, 2007. Clave: A I.F. = 3.877
103. **Martínez de Lagrán M**, Bortolozzi A, Millán O, Gispert JJ, Arbonés M, González JR, Artigas F, **Dierssen M** Dopaminergic Deficiency In A Dual-Specificity Tyrosine-Phosphorylated And Regulated Kinase 1A Heterozygous Mice (Dyrk1A^{+/-}) *Genes, Brain, Behav*. 6: 569-78, 2007. Clave: A I.F. = 3.795
104. **Dierssen M**, Gratacòs M, **Sahún I**, Martín M, Armengol L, **Gallego X**, **Amador-Arjona A**, **Martínez de Lagrán M**, Murtra P, Pujana MA, Ferrer I, Martínez-Cué C, Flórez J, Maldonado R, Fillat C, Estivill X. Overexpression of NTRK3 Increases

- Anxiety-Like Behavior and Alters Monoaminergic Circuits in Mice. *Neurobiol. Disease*. 24: 403-18, 2006. Clave: A I.F. = 4.518
105. **Dierssen M, de Lagran MM**. DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis. *TheScientificWorld Journal* 6: 1911-22, 2006. Clave: A
106. **Dierssen M**, Ramakers G Dendritic pathology in mental retardation: from molecular genetics to neurobiology. *Genes Brain Behav.* 5 Suppl 2: 48-60, 2006. Clave: A I.F. = 3.795
107. Lumbreras M, Baamonde C, Martínez-Cué C, Lubec G, Cairns N, Sallés J, **Dierssen M**, Flórez J Brain G protein-dependent signaling pathways in Down syndrome and Alzheimer's disease. *Amino Acids*. 31: 449-56, 2006. Clave: A I.F. = 3.877
108. **Dierssen M**, Ortiz Abalia J, Arqué G, **Martínez de Lagran M**, Fillat C. Pitfalls and hopes in Down syndrome Therapeutic approaches: In the search for evidence-based treatments. *Behavioural Genetics*. 36: 454-68, 2006. Clave: A I.F. = 3.117
109. Ferrer I, Barrachina M, Puig B, **Martínez de Lagrán M**, Martí E, Gómez-Isla T, Avila J, **Dierssen M** Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Dementia with Lewy bodies, Pick disease and related transgenic models. *Neurobiol. Disease* 20: 392-400, 2005. Clave: A I.F. = 4.518
110. Benavides-Piccione R, Elston GN, Arbones ML, Fotaki V, Estivill X, DeFelipe J, **Dierssen M**. Alterations in the phenotype of neocortical pyramidal cells in the DYRK1A^{+/-} mouse. *Neurobiol. Disease* 20:115-122, 2005. Clave: A I.F. = 4.518
111. Ayberk Kurt M, Ilker Kafa M, **Dierssen M**, Davies DC. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. *Brain Res*. 1022: 101-9, 2004. Clave: A I.F. = 2.463
112. Benavides-Piccione R, Ballesteros I, **Martínez de Lagrán M**, Elston G, Estivill X, Fillat C, DeFelipe J, **Dierssen M** On dendrites in Down syndrome and DS murine models: a spiny way to learn. *Prog. Neurobiol.* 74: 111-126, 2004. Clave: A I.F.= 9.140
113. Fotaki V, **Martínez de Lagrán M**, Estivill X, Arbonés M, **Dierssen M** Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity *Behav. Neurosci. J.* 118: 815-21, 2004. Clave: A I.F. = 2.874
114. **Martínez de Lagrán M**, Altafaj X, **Gallego X**, Martí E, Estivill X, Fillat C, **Dierssen M** Motor phenotypic alterations in TgDyrk1A transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. *Neurobiol. Disease* 15: 32-142, 2004. Clave: A I.F. = 4.518

115. **Dierssen M** Editor of Special Interest Section: Down syndrome, postgenomic approaches to neurobiological problems. *Genes, Brain Behav.* 2: 152-156, 2003. Clave: E I.F. = 3.795
116. Unterberger U, Lubec G, **Dierssen M**, Stoltenburg-Didinger G, Farreras JC, Budka H The cerebral cortex in Fetal Down Syndrome *J. Neural Transm. Suppl.* 67: 159-163, 2003. Clave: A I.F. = 2.259
117. **Dierssen M**, Benavides-Piccione R, Martínez-Cué C, Estivill X, Flórez J, Elston GN, DeFelipe J Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. *Cerebral Cortex* 13: 758-64, 2003. Clave: A I.F. = 6.979
118. Martí E, Altafaj X, **Dierssen M**, de la Luna S, Fotaki V, Alvarez M, Pérez-Riba M, Ferrer I, Estivill X Dyrk1a expression pattern supports specific roles of this kinase in the adult central nervous system. *Brain Res.* 964: 250-63, 2003. Clave: A I.F. = 2.463
119. Fountoulakis M, Juranville JF, **Dierssen M**, Lubec G Proteomic analysis of the fetal brain *Proteomics.* 2: 1547-76. 2002. Clave: A I.F. = 4.426
120. Fotaki V, **Dierssen M**, Alcantara S, Martinez S, Marti E, Casas C, Visa J, Soriano E, Estivill X, Arbones ML Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice *Mol. Cell Biol.* 22: 6636-47, 2002. Clave: A I.F. = 5.979
121. Martínez-Cue C, Baamonde C, Lumbreras M, Paz J, Davisson MT, Schmidt C, **Dierssen M**, Florez J Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome *Behav. Brain Res.* 134: 185-200, 2002. Clave: A I.F. = 3.220
122. Baamonde C, Lumbreras MA, Martínez-Cue C, Vallina IF, Florez J, **Dierssen M** Postnatal handling induces long-term modifications in central beta-noradrenergic signalling in rats *Stress.* 5: 137-47. 2002. Clave: A I.F. = 3.205
123. Garcia-Calatayud S, Ruiz JI, Garcia-Fuentes M, **Dierssen M**, Florez J, Crespo PS Long-chain polyunsaturated fatty acids in rat maternal milk, offspring brain and peripheral tissues in essential fatty acid deficiency *Clin. Chem. Lab. Med.* 40: 278-84, 2002. Clave: A I.F.= 1.886
124. **Dierssen M**, Fotaki V, **Martínez de Lagrán M**, Gratacòs M, Fillat C, Estivill X Neurobehavioral development of two mouse lines commonly used in transgenic studies. *Pharmacol. Biochem. Behav.* 73: 19-25, 2002. Clave: A I.F.= 2.967
125. **Dierssen M**, Marti E, Pucharcos C, Fotaki V, Altafaj X, Casas K, Solans A, Arbones ML, Fillat C, Estivill X Functional genomics of Down syndrome: a multidisciplinary approach. *J. Neural Transm.* 61: 131-48, 2001. Clave: A I.F. = 2.259

126. Ruiz de Azua I, Lumbreras MA, Zalduegui A, Baamonde C, **Dierssen M**, Florez J, Salles J Reduced phospholipase C-beta activity and isoform expression in the cerebellum of TS65Dn mouse: a model of Down syndrome. *J. Neurosci. Res.* 66: 540-50, 2001. Clave: A I.F. = 2.986
127. **Dierssen M**, Fillat C, Crnic L, Arbones M, Florez J, Estivill X Murine models for Down syndrome. *Physiol. Behav.* 73: 859-71, 2001. Clave: A I.F. = 3.295
128. Altafaj X, **Dierssen M**, Baamonde C, Marti E, Visa J, Guimera J, Oset M, Gonzalez JR, Florez J, Fillat C, Estivill X Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. *Hum. Mol. Genet.* 10: 1915-23, 2001. Clave: A I.F. = 7.386
129. Weitzdoerfer R, **Dierssen M**, Fountoulakis M, Lubec G Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. *J. Neural Transm.* 61: 59-70, 2001. Clave: A I.F. = 2.259
130. Weitzdoerfer R, Stolzlechner D, **Dierssen M**, Ferreres J, Fountoulakis M, Lubec G Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down syndrome brain. *J. Neural Transm.* 61:347-59, 2001. Clave: A I.F. = 2.259
131. Engidawork E, Baiic N, Fountoulakis M, **Dierssen M**, Greber-Platzer S, Lubec G Beta-amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect. *J. Neural Transm.* 61: 335-46, 2001. Clave: A I.F. = 2.259
132. Yoo BC, Fountoulakis M, **Dierssen M**, Lubec G Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein 1. *J Neural Transm.* 61:321-34, 2001. Clave: A I.F. = 2.259
133. Cheon MS, Fountoulakis M, **Dierssen M**, Ferreres JC, Lubec G Expression profiles of proteins in fetal brain with Down syndrome. *J Neural Transm.* 61: 311-9, 2001. Clave: A I.F. = 2.259
134. Lubec B, Yoo BC, **Dierssen M**, Balic N, Lubec G Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotonergic innervation. *J. Neural Transm.* 61: 303-10, 2001. Clave: A I.F. = 2.259
135. Cheon MS, Fountoulakis M, Cairns NJ, **Dierssen M**, Herkner K, Lubec G Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. *J. Neural Transm.* 61: 281-8, 2001. Clave: A I.F. = 2.259
136. Kim SH, **Dierssen M**, Ferreres JC, Fountoulakis M, Lubec G Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome

- brains. *J. Neural Transm.* 61: 273-80, 2001. Clave: A I.F. = 2.259
137. Engidawork E, Balic N, Juranville JF, Fountoulakis M, **Dierssen M**, Lubec G Unaltered expression of Fas (CD95/APO-1), caspase-3, Bcl-2 and annexins in brains of fetal Down syndrome: evidence against increased apoptosis. *J. Neural Transm.* 61: 149-62, 2001. Clave: A I.F. = 2.259
138. Engidawork E, Juranville JF, Fountoulakis M, **Dierssen M**, Lubec G Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome. *J. Neural Transm.* 61: 117-30, 2001. Clave: A I.F. = 2.259
139. Kim SH, Fountoulakis M, **Dierssen M**, Lubec G. Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains. *J. Neural Transm.* 61: 109-16, 2001. Clave: A I.F. = 2.259
140. Fuentes JJ, **Dierssen M.**, Pucharcós C, Fillat C, Casas C, Estivill X, Pritchard M Application of Alu-splice PCR on 21 chromosome: *DSCR1* and *Intersectin*. *J. Neural Trans.* 57: 337-352, 2000. Clave: A I.F. = 2.259
141. Chrast R, Scott HS, Papasavvas MP, Rossier C, Antonarakis ES, Barras C, Davisson MT, Schmidt C, Estivill X, **Dierssen M**, Pritchard M, Antonarakis SE The mouse brain transcriptome by Serial Analysis of Gene Expression (SAGE): Differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. *Genome Res.* 10: 2006-2021, 2000. Clave: A I.F. = 11.342
142. Kurt MA, Davies DC, Kidd M, **Dierssen M**, Flórez J Synaptic Deficit in the Temporal Cortex of Partial Trisomy 16 (Ts65Dn). Mice *Brain Res.* 858: 191-197, 2000. Clave: A I.F. = 2.463
143. Martínez-Cué C, Baamonde C, Vallina IF, **Dierssen M**, Flórez J. A murine model for Down syndrome shows reduced responsiveness to pain. *Neuroreport* 10: 1119-1122, 1999. Clave: A I.F. = 1.805
144. Baamonde C, Lumbreras M, Martínez-Cué C, Vallina IF, García-Calatayud S, Flórez J, **Dierssen M** Acute effect of postnatal manipulation on central beta-adrenoceptor transmission *Stress* 3:147-162, 1999. Clave: A I.F. = 3.205
145. Escorihuela RM, Martínez-Cué C, Vallina IF, Baamonde C, **Dierssen M**, Tobeña A, Flórez J, Fernández-Teruel A Impaired short- and long-term memory in Ts65Dn mice. *Neurosci. Lett.* 247: 171-174, 1998. Clave: A I.F. = 2.114
146. Insausti AM, Megías M, Crespo D, Cruz-Orive LM, **Dierssen M**, Vallina IF, Insausti R, Flórez J Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. *Neurosci. Lett.* 253: 1-4, 1998. Clave: A I.F. = 2.114
147. **Dierssen M**, Vallina IF, Baamonde C, García-Calatayud S, Lumbreras MA, Flórez J

- Alterations of central noradrenergic transmission in Ts65Dn mouse, a genetic model for Down syndrome *Brain Res.* 16: 33-44, 1997. Clave: A I.F. = 2.463
148. Megías M, Verduga R, **Dierssen M**, Flórez J, Insausti R, Crespo D Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice *Neuroreport* 8: 3475-78, 1997. Clave: A I.F. = 1.805
149. **Dierssen M**, Vallina I, Baamonde C, Lumbreras MA, Martínez-Cué MC, García-Calatayud S, Flórez J. Impaired cyclic AMP production in the hippocampus of a Down syndrome murine model. *Dev. Brain Res.* 95: 122-124. 1996. Clave: A I.F. = 2.463
150. **Dierssen M**, Vivas NM, Màrmol F, Sallés J, Badia A. The action of THA on noradrenergic effector systems: its interaction with cholinergic transmission in brain. *Neuropharmacology* 34: 367-375, 1995. Clave: A I.F. = 3.909
151. Escorihuela RM, Fernández-Teruel A, Tobeña A, Vivas NM, Màrmol F, Badia A, **Dierssen M** Early environmental enrichment produces long lasting neurochemical changes on β -adrenoceptor transduction system. *Neurobiol. Learn. Mem.* 64: 49-57, 1995. Clave: A I.F. = 3.479
152. Escorihuela RM, Fernández-Teruel A, Vallina IF, Baamonde C, **Dierssen M**, Tobeña A, Flórez J A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. *Neurosci. Lett.* 199: 143-146, 1995. Clave: A I.F. = 2.114
153. Aguado F, Badia A, Baños JE, Bosch F, Bozzo C, Camps P, Contreras J, **Dierssen M**, Escolano C, Görbig D.M, Vivas NM Synthesis and evaluation of tacrine-related compounds for the treatment of Alzheimer's disease. *Eur. J. Med. Chem.* 29: 205-221, 1994 . Clave: A I.F. = 3.269
154. Vivas NM, Màrmol, F, Badia A, **Dierssen M** Differential effects of physostigmine and THA on β -adrenoceptor transduction system. *European J. Mol. Pharmacol.* 245: 9-13, 1993. Clave: A I.F. = 2.585
155. Gascón S, **Dierssen M**, Màrmol F, Vivas NM, Badia A Effects of age on α 1-adrenoceptor subtypes in the rat ventricular muscle. *J. Pharm. Pharmacol.* 45:907-909, 1993. Clave: A I.F. = 1.742
156. Ruiz F, **Dierssen M**, Flórez J, Hurlé MA. The calcium channel agonist BAY K 8644 induces central respiratory depression in cats, an effect blocked by naloxone. *Eur. J. Pharmacol.* 240:155-161, 1993 . Clave: A I.F. = 2.585
157. Ruiz F, **Dierssen M**, Flórez J, Hurlé M Potentiation of acute respiratory depression and reversion of tolerance by the calcium antagonist nimodipine in awake rats. *Naun-Schmied. Arch. Pharmacol.* 348: 633-637. 1993. Clave: A I.F. = 2.631
158. **Dierssen M**, Màrmol F, Vivas NM, Clos V, Badia A Posttrain administration of 9-amino-1,2,3,4-tetrahydroacridine enhances passive avoidance retention and

- decreases β -adrenoceptor linked cyclic AMP formation in middle-aged rats. *Brain Res.* 586: 117-120,1992. Clave: A I.F. = 2.463
- 159.**Dierssen M**, Màrmol F, Vivas NM, Clos MV, Gascón S, Badia A Acute effects of tetrahydroaminoacridine on β adrenoceptor linked cyclic AMP accumulation in brain of young and senescent rats. *Neurosci. Lett.* 132:51-54, 1991. Clave: A I.F. = 2.114
- 160.**Dierssen M**, Ruiz F, Flórez J, Hurlé MA Calcium channel modulation by dihydropyridines modifies sufentanil-induced respiratory depression in cats. *Eur. J. Pharmacol.* 198: 149-155, 1991. Clave: A I.F. = 2.585
- 161.**Dierssen M**, Flórez J, Hurlé MA Influence of calcium channel modulation on opiate analgesia and tolerance *Naun- Schmied. Arch. Pharmacol.* 342: 559-565, 1990. Clave: A I.F. = 2.631
- 162.**Dierssen M**, Flórez J, Hurlé MA Lack of interaction between cholecystokinin and opioid systems on the respiratory function. *Rev. Esp. Fisiol.* 45: 185-190, 1989 Clave: A
- 163.Hurlé MA, **Dierssen M**, Morin-Surun MP, Oceja C, Flórez J Respiratory actions induced by cholecystokinin at the brain stem level. *Peptides* 9: 809-815, 1988. Clave: A I.F. = 2.551
- 164.Hurlé MA, **Dierssen M**, Flórez J Mechanism of the respiratory action of pentobarbital at the medullary and pontine levels. *Eur. J. Pharmacol.* 125: 225-232, 1986. Clave: A I.F. = 2.585

Libros y capítulos de libro

1. Down Syndrome: From Understanding the Neurobiology to Therapy. Progress in Brain Research Volume 197, Pages 2-262 (2012) **Edited by Mara Dierssen and Rafael De La Torre. Elsevier, 2012**
2. **Dierssen M**, Benavides-Piccione R, Martínez-Cué C, Estivill X, Baamonde C, Fillat C, **Martínez de Lagrán M**, Altafaj X, Flórez J, Elston G, DeFelipe J Genotype–phenotype neural correlates in trisomy 21 In: The Adult with Down Syndrome. A new challenge for society. Edited by Jean A. Rondal, Alberto Rasore-Quartino and Salvatore Soresi. Whurr Publishers, pages 15-30, London. 2004
3. Flórez J. **Dierssen M**. Cerebro disminuido: el valor de la emoción y la motivación. En: “El Cerebro sintiente” Ed. F. Mora. capítulo 6, pp. 135-151. *Ariel Neurociencia*. Barcelona. 2000
4. Martínez-Cué C, Baamonde C, Lumbreras MA, Paz J, **Dierssen M**, Flórez J Modelos animales de síndrome de Down: perspectivas terapéuticas In: *La Farmacología Española del año 2000* Libro Homenaje al Profesor Pedro Sánchez

- García. Publ. Universidad autónoma de Madrid 2000, p. 223-238. Madrid. 2000
5. **Dierssen M**, M Pritchard, C Fillat, M Arbonés, JM. Aran, J Flórez, X Estivill. Modelling Down syndrome in mice. En: Gerlai, R., Crusio, W. eds. *Molecular-Genetic Techniques for Brain and Behavior Research, Elsevier*. 1999
 6. Fuentes JJ, **Dierssen M**, Pucharcós C, Fillat C, Casa C, Estivill X, Pritchard M. Application of Alu-splice PCR on 21 chromosome: DSCR1 and Intersectin. In: *The Molecular Biology of Down syndrome brain. Springer Verlag, Viena*. 1999
 7. **Dierssen M**, Flórez J. Fármacos nootropos y neuroprotectores. Farmacología de las conductas anormales. In: Farmacología Humana (3 edición). Ed. J. Flórez. *Masson-Salvat*. 1997
 8. Flórez, J, Escorihuela RM, Baamonde C, Vallina IF, Martínez-Cué C, Lumbreras M, **Dierssen M**. Modelos animales de síndrome de Down: soluciones e incertidumbres. In: Síndrome de Down: biología conducta y educación Ed. J. Flórez, M.V. Troncoso, M. Dierssen. *Ediciones Masson-Salvat*, pp 49-58. 1996
 9. Escorihuela R, Fernández-Teruel A, Vallina I, Baamonde C, Lumbreras M, Martínez-Cué C, **Dierssen M**, Tobeña A, Flórez J. Caracterización conductual del ratón Ts65Dn: un modelo animal de síndrome de Down. In: Síndrome de Down: biología conducta y educación Ed. J. Flórez, M.V. Troncoso, M. Dierssen. *Ediciones Masson-Salvat*, pp 77-88. 1996.
 10. **Dierssen M**, Vallina IF, Baamonde C, García-Calatayud S, Lumbreras M, Montero JJ, Crespo D, Megías M, Flórez J. El ratón Ts65Dn: neuroquímica y morfología cerebrales. In: Síndrome de Down: biología conducta y educación Ed. J. Flórez, M.V. Tromcoso, M. Dierssen. *Ediciones Masson-Salvat*, pp 59-78. 1996.
 11. Flórez J, Troncoso MV, **Dierssen M**. La investigación española sobre el síndrome de Down: una visión panorámica. In: Síndrome de Down: biología conducta y educación Ed. J. Flórez, M.V. Tromcoso, M. Dierssen. *Ediciones Masson-Salvat*, 1-12. 1996.
 12. Estivill X, Fuentes JJ, Guimerá J, Nadal M, Milà M, Ballesta F, Aledo R, Solans A, Domènech A, Casas K, Pucharcós C, Puig A, Planas AM, Ferrer I, Fillat C, Pérez M, **Dierssen M**, Flórez J, Pritchard M. Disección molecular del cromosoma 21 humano y del síndrome de Down. In: Síndrome de Down: biología conducta y educación Ed. J. Flórez, M.V. Tromcoso, M. Dierssen. *Ediciones Masson-Salvat*, pp 13-24. 1996.
 13. Flórez J, Troncoso MV, **Dierssen M**, **EDS, 248 pág.** Síndrome de Down: biología conducta y educación. *Ediciones Masson-Salvat*, pp 13-24. 1996.
 14. **Dierssen M**, Fernández-Teruel A, Tobeña A, Vivas NM, Màrmol F, Badia A, Sallés J. Escorihuela Central noradrenergic mechanisms involved in pharmacological and

- psychological interventions used to restore cognitive deficits in middle-aged rats. In: *Deterioration, stability and regeneration of the brain during normal aging*. Eds. P. Coleman, M. Nieto-Sampedro, F. Mora. Centre for International Meetings on Biology. Instituto Juan March de Estudios e Investigaciones. Ediciones Peninsular, Madrid, pp 65. 1994.
15. **Dierssen M.** Farmacodinamia. In: *Farmacología Ócular*. M. March Pujol y J. E. Baños Díez. Eds. *Polítex Col.lecció. Area de Biologia i Mineralogia. Ediciones UPC*, 25: 45-52, Barcelona. 1994
 16. **Dierssen M.** Farmacología de la acomodación. In: *Farmacología Ócular*. M. March Pujol y J. E. Baños Díez Eds. *Polítex Col.lecció. Area de Biologia i Mineralogia. Ediciones UPC*, 25: 169-172, Barcelona. 1994
 17. **Dierssen M**, Sallés J, Vivas N, Màrmol F, Badia A. Nuevos enfoques en la terapia de reposición de neurotransmisores en la enfermedad de Alzheimer: influencia de la tacrina sobre el balance de respuesta noradrenérgico-colinérgico en el SNC. *Farmacología del SNC*, 8(4):125-142. 1994
 18. Sallés J, **Dierssen M.** Neurobiología del abuso de anfetaminas y sustancias derivadas. In: *Psicoestimulantes: cocaína, anfetaminas y xantinas. Avances en Farmacología de drogodependencias*, Eds. *J. Meana y F. Barturen*. Instituto Deusto de Drogodependencias, Universidad de Deusto. pp: 47-87. 1993.
 19. Flórez J, **Dierssen M**, Hurlé MA. Opiate analgesia and calcium channel modulation by dihydropyridines under acute and tolerant conditions. *Progress in Clinical and Biological Research*, 328: 461-464. 1990
 20. Hurlé MA, **Dierssen M**, Ruíz F, Flórez J. Influence of calcium channel agonists on the opiate activity at the respiratory centers of cats. *New leads in opioid research*, Eds. J.M. Van Reed, A.H. Mulder, V.M. Wiegant T.B. Van Wimersma, pp: 344-346. 1990
 21. **Dierssen M**, Flórez J, Hurlé MA. Blockade of calcium channel with nimodipine enhances opiate analgesia in naive and tolerant rats. *Advances in the Biosciences*, 75: 308-311. 1989
 22. Flórez J, **Dierssen M**, Hurlé MA. Influence of nimodipine on the respiratory effect of sufentanil at the brain-stem level. *Advances in the Biosciences*, 75: 535-539, 1989.
 23. Flórez J, **Dierssen M**, Hurlé MA. Calcium antagonists: actions in the Central Nervous System. In: *Recent advances in pharmacology and therapeutics* Eds. M. Velasco, A. Israel, E. Romero, H. Silva, pp: 77-82. 1989. Elsevier Science Publisher B.V. (Biomedical Division)
 24. Hurlé MA, **Dierssen M**, Morin-Surun MP, Flórez J. Respiratory actions of

cholecystokinin and its interaction with opioids at the brain-stem level. In: *"Control of breathing during sleep and anesthesia"*, Eds.: W.A. Karczewski, P. Grieb, J. Kulesza y G. Bonsignore. *Plenum Press*, N. York, 155-158. 1988

Publicaciones en revistas no indexadas

1. **Dierssen M, Azcona G**, Fillat C, Toiber D, Soreq H. Bases moleculares de la neuropatología del síndrome de Down: implicación de DYRK1A. Publicación del VI Premio «Jaime Blanco» de investigación en el síndrome de Down. Editorial Nueva Imprenta, Madrid.
2. **Martínez de Lagrán M**, Bortolozzi A, Gispert J, Millán O, Artigas F, Fillat C, **Dierssen M** El envejecimiento en el síndrome de Down: Dyrk1A como gen candidato para el declive cognitivo *Revista Internacional Síndrome de Down*, 12: 34-40. 2008
3. **Dierssen M**, Flórez J Interacción del entorno y maduración neuronal en el síndrome de Down *Mente y Cerebro*, nº 23, pp: 16 – 22. 2007
4. Flórez J, **Dierssen M** La transcripción de genes en las personas con síndrome de Down: tan iguales y tan diferentes *Revista Síndrome de Down: Revista española de investigación e información sobre el Síndrome de Down*, ISSN 1132-1911, Nº. 90, pags. 78-83. 2006
5. **Dierssen M**, Benavides-Piccione R, Martínez-Cué C, Estivill X, Flórez J, Elston GN, DeFelipe J Alteraciones de la microarquitectura de la corteza cerebral en el ratón Ts65Dn, un modelo murino de síndrome de Down: efectos del enriquecimiento ambiental *SD, Revista médica internacional sobre el Síndrome de Down*. 7(2): 18-25. 2003
6. Estivill X, Arbonés ML, de la Luna S, Fuentes J, Fillat C, Guimerá J, Aran JM, Pérez-Riba M, Pritchard M, **Dierssen M** Disección molecular del cromosoma 21 y modelos murinos del síndrome de Down *Progresos en Diagnóstico Prenatal* , 11: 162-166. 2000
7. **Dierssen M**, Flórez J. Novena reunión internacional sobre el cromosoma 21 y el síndrome de Down. *Revista Síndrome de Down* 17: 124-128. 2000.
8. **Dierssen M**, Fillat C, Pritchard M, Arbonés ML, Aran JM, Flórez J, Estivill X. Generació i caracterització de models de la síndrome de Down en el ratolí. *Revista Médica Internacional sobre la síndrome de Down*, 17: 18-24. 1999
9. **Dierssen M**. El desarrollo cerebral de un ratón trisómico. *Revista del Síndrome de Down*, 12: 38-39. 1995.
10. **Dierssen M**. Las bases neurobiológicas de la intervención temprana. *Revista del*

Síndrome de Down, 11: 3-9.1994

11. **Dierssen M**, Baamonde C, García-Pelayo P. El éxtasis: toxicidad y adictividad. *Revista Proyecto Hombre*, 6:37-44, 1994
12. Flórez J, **Dierssen M**. Agentes nootrópicos y los llamados vasodilatadores cerebrales. *Información terapéutica del Sistema Nacional de Salud*, 18: 169-176. 1994

Otras publicaciones

1. **Dierssen M**. Estado anímico y vídeo/memoria en condiciones extremas. La Antártida. Editorial ACTAR. Arts Santa Mónica, Universidad de Barcelona i la Fundació Bosch i Gimpera, Barcelona.
2. **Dierssen M**. El cerebro humano: un acontecimiento evolutivo especial. Paradigma, Universidad de Málaga (ISSN: 1885-7604).
3. **Dierssen M**. Una visión del arte desde la neurobiología de la discapacidad intelectual. Programas de educación especial de centros de arte contemporáneo. Centre d'Art la Panera de Lleida, conjuntamente con el Centro de Arte y Naturaleza de Huesca, EsBaluard Museu d'Art Modern i Contemporani de Palma y el Centre d'Art Contemporain Languedoc-Roussillon de Sète (Francia).
4. **Dierssen M**. La Música: ¿un impulso básico o un elemento clave en el cerebro humano? *Revista Médica Internacional Sobre El Síndrome De Down*, 13: 17 (Editorial), 2009
5. **Dierssen M** En Resonancia. Música en tu cerebro. En prensa. 2009
6. **Dierssen M**, Pumarola, M Sixto Obrador y la Neurocirugía Científica en España colección: "Neurocientíficos españoles" (CSIC)
7. **Dierssen M** Unidad didáctica "Viaje al Universo Neuronal" Fundación Española de Ciencia y Tecnología, 2007, Dierssen M, coordinadora.
8. **Dierssen M**, Neurobiología de la experiencia musical La musica y la mente humana *BIOMEDIA*, 2004
9. **Dierssen M**. La Música y la Mente Humana Eufonía: Didáctica de la música, ISSN 1135-6308, N° 21, pags. 85-97. 2001
10. **Dierssen M**. El Cerebro Artístico. Ediciones El País